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ABSTRACT OF THE DISSERTATION 
 
The Effect of Circadian Therapies 
in Models of Neurodegenerative Disease 
 
by 
 
Daniel Steven Whittaker 
Doctor of Philosophy in Molecular, Cellular, and Integrative Physiology 
University of California, Los Angeles, 2019 
Professor Christopher S. Colwell, Chair  
 
Huntington’s Disease (HD) is an autosomal dominant disorder caused by excessive CAG 
repeats in the gene encoding the huntingtin protein which leads to progressive 
neurodegeneration that inflicts cognitive, psychiatric, cardiovascular and motor dysfunction. 
There is currently no treatment to prevent or delay the course of the disease. Neuronal loss in 
the striatum is thought to be responsible for the abnormal motor control present in HD patients, 
though the pathophysiology behind the non-motor symptoms is still unclear. Disturbances in 
sleep-wake cycles are common among HD patients with reports of delayed sleep onset, 
frequent bedtime awakenings, and excessive fatigue, and these disruptions are recapitulated in 
mouse models. Because circadian dysfunction manifests early in the disease in both patients 
and mouse models, we sought to determine if early interventions that improve circadian 
rhythmicity could benefit HD symptoms and delay disease progression.  
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Evidence of altered histaminergic signaling in HD patients suggests that this pathway 
may contribute to disrupted rhythms in arousal. Utilizing the Q175 mouse model of HD, we 
demonstrated that nightly treatment with a histamine-3 receptor antagonist/inverse agonist 
improved several behavioral measures of HD including strengthening activity rhythms, cognitive 
performance, and mood, as well as reducing inappropriate activity during the normal sleep 
time. Our findings suggest that drugs targeting the histamine-3 receptor system may be 
beneficial as cognitive enhancers in the management of HD. 
One of the most powerful regulators of the circadian system is the daily feed/fast cycle, 
and in two separate studies we found that three months of time-restricted feeding (6-hours of 
feeding in the middle of the active phase followed by 18-hours fasting) improved the 
sleep/wake cycle, motor symptoms, and autonomic function in both the Q175 and BACHD 
mouse models. 
Finally, we sought to determine whether a ketogenic diet was sufficient to impart motor 
performance and sleep/wake rhythm benefits in BACHD mice similar to those observed under 
TRF. We found that the ketogenic diet improves circadian dysfunction as well as motor 
symptoms in the BACHD mouse model. 
Altogether, these studies support the hypothesis that early interventions that improve 
sleep/wake timing and circadian rhythmicity can ameliorate a range of symptoms of HD and 
related neurodegenerative disorders. 
iv 
 
The dissertation of Daniel Steven Whittaker is approved 
Gene D. Block 
Cristina A. Ghiani 
Fernando Gomez-Pinilla 
Elaine Yih-Nien Hsiao 
Christopher S. Colwell, Committee Chair  
 
 
University of California, Los Angeles 
2019  
v 
 
Table of Contents 
List of Figures .................................................................................................................... vi 
List of Tables ................................................................................................................... viii 
List of Acronyms ................................................................................................................ ix 
Acknowledgments ............................................................................................................ xiii 
VITA ............................................................................................................................... xiv 
Chapter 1: Introduction ...................................................................................................... 1 
Chapter 2: Possible use of a histamine-3 receptor antagonist for the management of nonmotor 
symptoms in the Q175 mouse model of Huntington’s disease ...............................................18 
Chapter 2 bibliography ...................................................................................................32 
Chapter 3: Time-restricted feeding improves circadian dysfunction as well as motor symptoms 
in the Q175 mouse model of Huntington’s disease ...............................................................36 
Chapter 3 bibliography ...................................................................................................50 
Chapter 4: Circadian-based treatment strategy effective in the BACHD mouse model of 
Huntington’s disease .........................................................................................................53 
Chapter 4 bibliography ...................................................................................................69 
Chapter 5: A ketogenic diet improves circadian dysfunction as well as motor symptoms in the 
BACHD mouse model of Huntington’s disease ......................................................................75 
Chapter 6: Conclusions .................................................................................................... 102 
Bibliography ................................................................................................................... 112 
 
  
vi 
 
List of Figures 
Figure 1: Figure 2-1: Serum concentrations of GSK189254 in Hom and Het Q175 mice. ..........24 
Figure 2: Figure 2-2: Chronic administration of GSK189254 strengthened daily activity rhythms 
in Hom and Het Q175 mice. ...............................................................................................25 
Figure 3: Figure 2-3: Chronic administration of GSK189254 improved some aspects of the daily 
rhythm in cage locomotor activity in Hom and Het Q175 mice...............................................27 
Figure 4: Figure 2-4: Chronic administration of GSK189254 alters the temporal pattern of sleep 
behavior in Q175 mice. ......................................................................................................28 
Figure 5: Figure 2-5: Chronic administration of GSK189254 improved exploratory behavior as 
measured by the open field test in Hom and Het Q175 mice. ................................................29 
Figure 6: Figure 2-6: Chronic administration of GSK189254 improved cognitive performance as 
measured by the T-maze in the Het Q175 mice. ..................................................................30 
Figure 7: Figure 2-7: Chronic administration of GSK189254 improved affect as measured by the 
tail suspension test in Hom Q175 mice. ...............................................................................31 
Figure 8: Chapter 3: Visual Abstract ...................................................................................37 
Figure 9: Figure 3-1: Locomotor activity rhythms were improved by the TRF regimen. ............42 
Figure 10: Figure 3-2: TRF prevented disease-caused awakening time without altering the 
amount of sleep behavior. .................................................................................................44 
Figure 11: Figure 3-3: Autonomic output rhythms were improved by the TRF regimen. ...........46 
Figure 12: Figure 3-4: TRF improved motor performance in the Q175 HD model. ...................47 
Figure 13: Figure 3-5: Altered expression level of multiple HD markers in the striatum of the 
Q175 HD model. ...............................................................................................................48 
Figure 14: Figure 4-1: Locomotor activity rhythms were improved by the TRF regimen. ..........60 
Figure 15: Figure 4-2: Sleep behavior was altered by the TRF protocol. .................................62 
vii 
 
Figure 16: Figure 4-3 Autonomic output rhythms from BACHD mice were improved by the TRF 
regimen. ..........................................................................................................................63 
Figure 17: Figure 4-4: TRF alters the peak phase, but not the amplitude, of the Per2::luC 
rhythms measured in peripheral organs in vivo. ...................................................................64 
Figure 18: Figure 4-5: TRF improved motor performance in the BACHD model. ......................66 
Figure 19. Figure 4-Supplemental figure 1: The temporal pattern of eating is altered in BACHD 
compared to WT controls. ..................................................................................................74 
Figure 20: Figure 5-1: TRF and KD evoke daily rhythms in serum ketones (βOHB). .................97 
Figure 21: Figure 5-2: Locomotor activity rhythms were improved by the KD. ........................98 
Figure 22: Figure 5-3: Sleep behavior was altered by the KD. ...............................................99 
Figure 23: Figure 5-4: KD improved motor performance in the BACHD model....................... 100 
Figure 24: Figure 5-Supplemental figure 1: Comparison of NIH-31 standard chow diet with KD.
 ..................................................................................................................................... 101 
Figure 25: Figure 6-1: Western blot and immunohistochemistry in BACHD brains show axonal 
and myelin loss early in disease progression. ..................................................................... 110 
Figure 26: Figure 6-2: Western blot and immunohistochemistry in BACHD brains suggests 
astroglial activation and a concurrent immune response in the brain. .................................. 110 
 
 
  
viii 
 
List of Tables 
Table 1-1: Summary of circadian phenotypes from mouse models of Huntington’s disease. .....17 
Table 2: Table 2-1: Selected behavioral values for WT control mice.......................................26 
Table 3: Table 3-1: List of distribution, statistical test, and power for each dataset analyzed in 
this study. ........................................................................................................................41 
Table 4: Table 3-2: Comparisons of age-matched WT under ad lib conditions to Q175 mice 
under ad lib or TRF regimen. .............................................................................................43 
Table 5: Table 3-3: Comparisons of age-matched WT under ad lib to regimen. ......................45 
Table 6: Table 3-4: TRF improved motor performance in the Q175 HD model. .......................47 
Table 7: Table 3-5: Top 10 canonical pathways and upregulators identified using IPA analysis in 
striatum of Q175 under TRF regimen. .................................................................................48 
Table 8: Table 3-6: Full dataset of expression of HD markers in the striatum of Q175 that are 
tested by using NanoString technology. ..............................................................................49 
Table 9: Table 4-1: Rhythms in locomotor activity and sleep behavior in BACHD mice were 
improved by TRF...............................................................................................................61 
Table 10: Table 4-2: TRF alters the peak phase but not the amplitude of the PER2::LUC 
rhythms measured in peripheral organs in the intact animal. ................................................65 
Table 11: Table 4-3: TRF alters some aspects of the PER2::LUC rhythms measured in culture in 
a tissue-specific manner. ...................................................................................................65 
Table 12: Table 4-4: TRF improved motor performance in the BACHD model. ........................67 
Table 13: Table 6-1: Primary antibodies were used at the following concentrations for 
immunohistochemistry (IHC) or western blot (WB): ........................................................... 111 
 
  
ix 
 
List of Acronyms 
a.u. arbitrary units  
AcAc acetoacetate  
ad lib/AL ad libitum 
Ala alanine 
AMPK 5' adenosine monophosphate-activated protein kinase 
ATP adenosine triphosphate  
AVP arginine vasopressin  
BBB blood–brain barrier  
BDNF  brain derived neurotrophic factor 
BK large conductance calcium-activated potassium channels  
BMAL1 brain and muscle aryl-hydrocarbon receptor nuclear translocator-like 1 
CAG cytosine, adenine, guanine 
cAMP  cyclic adenosine monophosphate 
CB  challenging beam 
CBT core body temperature 
CK1 casein kinase 1 
CLOCK  circadian locomotor output cycles kaput 
CREB cyclic adenosine monophosphate response element-binding protein 
CRY  cryptochrome 
CPT1A carnitine-palmitoyl transferase 1a 
D1 Dopamine Receptor D1 
DBP  D site of albumin promoter (Albumin D-Box) binding protein 
EEG electroencephalogram 
x 
 
EMG  electromyography 
FAA food-anticipatory activity  
GABA  gamma-aminobutyric acid 
GLUT  Glucose transporter 
GRP  gastrin-releasing peptide  
Gpe globus pallidus 
GSK189254 6‐[(3‐cyclobutyl‐2,3,4,5‐tetrahydro‐1H‐3‐benzazepin‐7‐yl)oxy]‐N‐methyl‐3‐
pyridinecarboxamide 
H3R  histamine‐3 receptor 
HA  histamine 
HBSS Hanks’ balanced salt solution  
HD  Huntington's disease 
HDAC histone deacetylase 
Het heterozygous 
HMGCS2 hydroxymethyl-glutaryl CoA synthase 2  
Hom homozygous 
HR heart rate 
Hrh3 Histamine receptor H3 
HRV heart rate variability 
Htt /HTT Mouse Huntingtin gene/protein 
HTT/HTT Human Huntingtin gene/protein 
IR infrared 
KCNMA1 potassium calcium-activated channel subfamily M alpha 1 
KD ketogenic diet 
xi 
 
LC3A microtubule-associated protein 1 light chain 3  
LD light/dark 
LFD low-fat diet 
LUC Luciferase 
lux measure of light intensity 
MCT medium chain triglyceride 
mHTT mutant Huntingtin protein 
mTOR mammalian Target of Rapamycin protein 
mM millimolar 
NN normal to normal interval 
NREM non-rapid eye movement sleep  
OF open field 
P70S6K Ribosomal protein S6 kinase beta-1 
PDK4  pyruvate dehydrogenase kinase 4 
PER period 
PER2 Period Circadian Regulator 2 
PK2 prokineticin 2 
PPARα peroxisome proliferator activated receptor alpha 
REM rapid eye movement sleep  
RI resident‐intruder 
RM ANOVA repeated-measures analysis of variance 
ROR  retinoic acid-related orphan receptor  
ROS reactive oxygen species  
SCOT succinyl-CoA: 3-oxoacid CoA transferase  
xii 
 
SCN suprachiasmatic nucleus 
SEM standard error of the mean  
SIRT1 sirtuin 1 
Sub gland submandibular gland 
TM T‐maze 
TMN tuberomammilary nucleus 
TRF time-restricted feeding 
TS tail suspension 
UCP3 uncoupling protein 3 
VIP vasoactive intestinal peptide 
VPAC2 vasoactive intestinal peptide receptor 2 
WT wild-type 
ZT zeitgeber time 
βOHB D-β-hydroxybutyrate  
µL  microliter  
xiii 
 
Acknowledgments 
The UCLA Molecular, Cellular, and Integrative Physiology (MCIP) Graduate Program 
provided financial as well as academic support. Takeda Pharmaceuticals provided support and 
materials for the research conducted in Chapter 2. The CHDI Foundation supported the 
research included in Chapters 3 and 4. The Graduate Student Grant Program award by the 
UCLA Brain Research Institute provided funds to support the ongoing mechanistic research. The 
Teaching Fellowship award by the UCLA Cluster Program in Undergraduate Education Initiatives 
provided year-long tuition for 2017 to 2018 and 2018 to 2019. 
Chapter three is a version of Wang, H.-B., Loh, D.H., Whittaker, D.S., Cutler, T., 
Howland, D., and Colwell, C.S. (2018). Time-restricted feeding improves circadian dysfunction 
as well as motor symptoms in the Q175 mouse model of Huntington’s disease. ENeuro 5. 
https://dx.doi.org/10.1523%2FENEURO.0431-17.2017. 
There were many people who provided support in immeasurable ways, and I will not, at 
this moment, thank everyone by name. I am grateful to Vikki Paschetto, who probably 
sacrificed much more than she ever meant to. Louise Levinson provided the early spark and 
inspiration. Katie Whittaker provided the support, the respite, the shoulder, the love, and so 
many other things that mothers do. My mentors and guides on this path have been and are 
many: Jim Tidball, Christopher Colwell, Cristina Ghiani, Dawn Loh, and many others. There 
were many who helped with the work and I would be remiss if I did not thank Huei Bin Wang. 
Yu Tahara always gave excellent feedback after listened to my many hours of intellectual 
rambling. Finally, I wish to express my deepest thanks to the many student, undergraduate, 
and graduate researchers who contributed to this work. 
  
xiv 
 
VITA Summer 2019 
DANIEL S. WHITTAKER 
 
EDUCATION 
Ph.D. candidate in Molecular, Cellular, and Integrative Physiology, College of Letters 
and Sciences, University of California, Los Angeles. Research interests: circadian biology, aging, 
therapeutic interventions that improve health span and quality of life through improving or 
delaying progression in neurodegenerative conditions and diseases. 
Bachelor of Science in Exercise Science and Biosciences, Summa cum laude, School of 
Kinesiology and Nutritional Science, California State University, Los Angeles. June, 2010. 
PUBLICATIONS 
Whittaker, D.S., Loh, D.H., Wang, H.-B., Tahara, Y., Kuljis, D., Cutler, T., Ghiani, C.A., 
Shibata, S., Block, G.D., and Colwell, C.S. (2018). Circadian-based treatment strategy 
effective in the BACHD mouse model of Huntington’s disease. J. Biol. Rhythms 33(5), 
535–554. 
Wang, H.-B., Loh, D.H., Whittaker, D.S., Cutler, T., Howland, D., and Colwell, C.S. (2018). 
Time-restricted feeding improves circadian dysfunction as well as motor symptoms in 
the Q175 mouse model of Huntington’s disease. ENeuro 5. 
Lee, F. Y., Wang, H.-B., Hitchcock, O. N., Loh, D. H., Whittaker, D. S., Kim, Y. S., Aiken, A., 
Kokikian, C., Dell'Angelica, E. C., Colwell, C. S., … Ghiani, C. A. (2018). Sleep/Wake 
disruption in a mouse model of BLOC-1 deficiency. Frontiers in neuroscience, 12, 759.  
Whittaker, D.S., Wang, H.-B., Loh, D.H., Cachope, R., and Colwell, C.S. (2017). Possible use 
of a H3R antagonist for the management of nonmotor symptoms in the Q175 mouse 
model of Huntington’s disease. Pharmacol. Res. Perspect. 5, e00344. 
Wang, H.-B., Whittaker, D.S., Truong, D., Mulji, A.K., Ghiani, C.A., Loh, D.H., and Colwell, 
C.S. (2017). Blue light therapy improves circadian dysfunction as well as motor 
symptoms in two mouse models of Huntington’s disease. Neurobiol. Sleep Circadian 
Rhythms 2, 39–52. 
Samengo G, Avik A, Fedor B, Whittaker D, Myung KH, Wehling-Henricks M, Tidball JG (2012) 
Age-related loss of nitric oxide synthase in skeletal muscle causes reductions in calpain 
S-nitrosylation that increase myofibril degradation and sarcopenia. Aging Cell 11:1036–
1045. 
ADDITIONAL RESEARCH EXPERIENCE 
University of California, Los Angeles. Dr. Melissa Spencer, PI. Investigate immune cell and 
cytokine origin, expression, and modulation in a model of muscular dystrophy. 4/2013 to 
8/2014. 
University of California, Los Angeles. Dr. Rachelle Crosbie-Watson, PI. Investigate the role of 
various proteins in neuromuscular junction stability and morphology in in a model of muscular 
dystrophy. 1/2013 to 4/2013. 
University of California, Los Angeles. Dr. Linda Baum, PI. Study the role of glycosylation in 
disease. 9/2012 to 1/2013. 
University of California, Los Angeles. Dr. James Tidball, PI. Research protein modifications and 
their roles in the regulation of skeletal muscle wasting and regeneration in a model of muscular 
dystrophy. 11/2010 to 9/2012. 
xv 
 
University of Southern California, Leonard Davis School of Gerontology. Undergraduate 
Research Assistant. Research Advisor: Dr. Valter Longo. Study novel cancer interventions at the 
cell and organism level in a mammalian model. 4/2010 to 7/2010.  
California State University, Los Angeles, Human Performance Laboratory. Undergraduate 
Research Assistant. Research Advisor: Dr. Nazareth Khodiguian. Investigate human blood 
buffering responses to intense training and high altitudes. 2/2008 to 7/2010. 
HONORS AND AWARDS 
Brain Research Institute Graduate Student Research Grant, $10,000, 2018-2019. 
NIH Pre-Doctoral Fellowship, 2012-2013. 
UCLA Graduate Fellowship, 2010-2011. 
American Veterans Memorial Scholarship, 2011, 2009. 
JVS Unites States Marine Corps Service Scholarship, 2007-2011. 
Phi Kappa Phi Love of Learning Scholarship, 2011. 
Golden Key International Honour Society Scholarship, 2010. 
Veterans United Scholarship, 2010. 
Ebell Scholarship, 2009-2010. 
Dean's List, CSULA, 2007-2010. 
CSULA School of Health and Human Services Certificate of Honor, 2009. 
UPromise Scholarship, 2008-2009. 
Sallie Mae Scholarship, 2008-2009. 
CSU Future Scholar Award, 2007.  
COLLEGE TEACHING EXPERIENCE 
4/19 to 7/19 (GE80) From Test Tube to Community, UCLA, Graduate Student Instructor. 
10/18 to 4/19 (GE80) Frontiers in Human Aging - Cluster Course, UCLA, Teaching Fellow. 
4/18 to 7/18 (GE80) From Test Tube to Community, UCLA, Graduate Student Instructor. 
10/17 to 4/18 (GE80) Frontiers in Human Aging - Cluster Course, UCLA, Teaching Fellow. 
4/17 to 7/17 (EEB186) Evolutionary Medicine, UCLA, Teaching Fellow. 
9/14 to 6/16 (LS1) Evolution, Ecology, and Biodiversity, UCLA, Teaching Fellow. 
7/12 to 9/12 (PhySci136) Exercise and Cardiovascular Function, UCLA, Teaching Associate. 
7/11 to 9/12 (PhySci5) Issues in Human Physiology, UCLA, Teaching Associate. 
9/10 to 9/12 (LS2) Cells, Tissues, and Organs, UCLA, Teaching Assistant. 
MILITARY HONORS 
Naval Achievement Medal 
Battle Efficiency “E” Award (multiple) 
Good Conduct Medal 
Sea Service Deployment Ribbon (multiple) 
Meritorious Promotion (multiple) 
Marine of the Quarter (multiple) 
Cold War Recognition Certificate 
Honor Man (multiple) 
Letter of Commendation (multiple)  
1 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Introduction 
  
2 
 
Chapter 1: Introduction 
Huntington’s disease (HD) is characterized by cognitive, psychiatric, cardiovascular, and 
motor dysfunction resulting from advancing neurodegeneration (Kuljis et al., 2012; Margolis and 
Ross, 2003). Mortality occurs on average 10 to 20 years after the onset of initial motor 
symptoms. The underlying pathology in HD is caused by a CAG repeat expansion within the first 
exon of the Huntingtin (HTT) gene. When translated, this produces a polyglutamine repeat and 
leads to protein misfolding, soluble aggregates, and inclusion bodies detected throughout the 
body (Ciammola et al., 2006; Saft et al., 2005). Huntingtin (HTT) is expressed throughout the 
body, with higher levels found in the brain than the peripheral tissues. In particular, HTT 
expression is found to be higher in brain regions with increased neuronal density, as well as 
being elevated in neurons versus glial cells (Li et al., 1993; Strong et al., 1993). Similarly, the 
mutant HTT protein (mHTT) is more abundant in neurons than in glial cells with aggregates 
demonstrating a comparable distribution (Bradford et al., 2010). In muscle, aggregates are 
found only in the nucleus of myocytes (Gutekunst et al., 1999). The accretion of mHTT leads to 
the dysfunction of a wide range of cellular processes as well as loss of many normal functions 
(Wright et al., 2017). Loss of neurons in the striatum has been well characterized and is 
considered the hallmark of HD pathology. However, both gray and white matter loss have been 
well described at different stages of HD progression: pre-symptomatic, early in disease, 
postmortem (Bartzokis et al., 2007; Bourbon-Teles et al., 2019; Di Paola et al., 2012; Phillips et 
al., 2016), suggesting that the effects of myelin loss might also be a significant factor in the 
course of the disease. 
HD symptoms manifest at different ages, with an average onset of motor symptoms and 
diagnosis at 40 years of age. Generally, the longer the CAG repeat, the earlier the age of onset 
and the greater the severity of the symptoms (Langbehn et al., 2010). Yet, even among 
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patients with the same CAG repeat length, there is a considerable range in the age of onset and 
severity of symptoms (Gusella et al., 2014; Wexler et al., 2004). Further, cognitive, affective, 
and other symptoms may arise up to two decades before the onset of motor symptoms 
(Paulsen, 2011; Paulsen et al., 2008). Such variability raises the possibility of environmental 
modifiers influencing the disease and suggests that appropriate and early disease management 
strategies can increase the health span of these patients. This possibility is important to pursue 
as there are currently no treatments to prevent or delay the disease course. 
Sleep disorders are extremely common in HD patients and have detrimental effects on 
the daily functioning and quality of life of patients and their caregivers (Aziz et al., 2010a; 
Cuturic et al., 2009; Goodman et al., 2011; Morton et al., 2005). These disruptions in the timing 
of sleep often become apparent years before the onset of the motor symptoms. One of the first 
signs of the disease in HD patients is a phase delay in the nightly rise in melatonin (Kalliolia et 
al., 2014) and, by the end of life, the central circadian clock (suprachiasmatic nucleus, SCN) 
shows evidence of degeneration (van Wamelen et al., 2014). In humans, it is extremely difficult 
to determine if the circadian system is dysfunctional and to explore the underlying mechanisms. 
In the field of HD research, a number of animal models of HD have been developed, each with 
strengths and weaknesses (Pouladi et al., 2013). Broadly speaking, mouse models of HD also 
exhibit a progressive and rapid breakdown of the circadian rest/activity cycle that closely mimics 
the condition observed in human patients, typified by loss of consolidated sleep, increased 
wakeful activity during the sleep phase, and more sleep during the active/awake phase (Table 
1).  
The research work in my dissertation uses two mouse models of HD. The first model, 
the Q175 mouse, is a knock-in model in which the human exon 1 sequence of the huntingtin 
gene is inserted into the mouse DNA with approximately 190 CAG repeats. Among the 
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numerous models available, the heterozygous (Het) Q175 offers the advantage of strong 
construct validity with a single copy of the mutation, genetic precision of the insertion, and 
control of mutation copy number. The Q175 Het become notably symptomatic around 6 months 
of age and reach end-stage disease at around 22 months (Menalled et al., 2012). 
The second model, the Bacterial artificial chromosome (BAC)-mediated transgenic 
mouse model (BACHD), is a transgenic mouse expressing the entire human HTT gene with 97 
mixed CAA–CAG repeats. The BACHD mouse offers the advantage of containing the human 
gene including all the regulatory elements. BACHD mice have a strong progressive phenotype 
starting at 2- to 3-months of age (Menalled et al., 2009). Prior studies have demonstrated that 
these are both strong preclinical models to examine the impact of circadian interventions on the 
disease trajectory (Kudo et al., 2011a; Loh et al., 2013; Menalled et al., 2009; Pouladi et al., 
2013). It is worth noting another well studied model, the R6/2 mouse, which contains N-
terminally truncated mutant Htt with a CAG repeat expansion (~125 repeats) within exon 1 of 
the huntingtin gene. The R6/2 model develops HD-like symptoms as early as 6 to 8 weeks of 
age and suffers rapid decline (Mangiarini et al., 1996). Because circadian dysfunction manifests 
early in the disease in both patients and mouse models, and based upon the hypothesis that 
circadian dysfunction interacts with HD pathophysiology and exacerbates HD-related symptoms, 
we sought to determine if early interventions that improve sleep/wake timing and circadian 
rhythmicity could benefit HD symptoms and modify the course of the disease. Before describing 
the interventions, I will provide some brief background on circadian rhythms that is relevant to 
the dissertation research. 
Robust circadian rhythms are important to our health and wellness, with many studies 
demonstrating that the disturbance of these cycles have broad negative impacts on the body. 
In mammals, the SCN in the hypothalamus contains the “master” oscillatory network necessary 
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for coordinating circadian rhythms throughout the body (Astiz et al., 2019; Challet, 2015; 
Colwell, 2011). The SCN is a bilaterally paired nucleus made up of tightly compacted, small-
diameter neurons just lateral to the third ventricle atop the optic chiasm. Anatomical studies 
generally support the division of the SCN into at least two subdivisions, including a ventral 
”core” and a dorsal ”shell” region. The core neurons are thought to act as an integrator of 
external input, receiving information from three major pathways: the retinohypothalamic tract, 
the geniculohypothalamic tract, and projections from the raphe nuclei. Core neurons 
communicate this environmental information to the rest of the SCN. These sensory processing 
ventral cells exhibit relatively low amplitude rhythms in clock gene expression. Many of the 
neurons that receive retinal input within the core SCN express the neuropeptides vasoactive 
intestinal protein (VIP) or gastrin-releasing peptide (GRP), as well as the neurotransmitter 
gamma-aminobutyric acid (GABA). In contrast, neurons of the dorsal shell appear to generate 
the most robust circadian oscillations, at least at the level of gene expression. The neurons in 
the shell express arginine vasopressin (AVP) or prokineticin 2 (PK2), as well as GABA. The fact 
that many core projections terminate on shell neurons supports the idea that interplay between 
these two centers is responsible for the output of circadian information from the SCN. The 
outputs of the SCN from both core and shell subpopulations largely travel to other hypothalamic 
regions, including the subparaventricular region and the paraventricular nuclei of the 
hypothalamus. These hypothalamic relay nuclei send projections throughout the nervous and 
endocrine systems, providing multiple pathways by which the SCN can convey temporal 
information to the brain and body (Astiz et al., 2019; Welsh et al., 2010).  
Circadian rhythms are driven by cell autonomous molecular feedback loops (Rosbash et 
al., 2007; Takahashi, 2017). At a molecular level, circadian rhythms are generated by an 
intracellular transcriptional/translational feedback loop, driving daily oscillations with a period of 
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approximately 24-hours (hr) in the expression of core clock proteins. Circadian locomotor 
output cycles kaput (CLOCK) and brain and muscle aryl-hydrocarbon receptor nuclear 
translocator-like 1 (BMAL1), the positive components of the clock, bind to E-box sequences and 
drive the expression of the negative elements, period (PER) and cryptochrome (CRY), which can 
inhibit their own transcription by repressing the CLOCK/BMAL1 heterodimer. Once the levels of 
PER and CRY are decreased, the new cycle of transcription/translation is started by 
CLOCK/BMAL1. BMAL1 expression is further regulated through repressed by the circadian 
nuclear receptor REV-ERBα, and activated by the retinoic acid-related orphan receptor (ROR). 
Further, post-translational modifications are crucial for regulating the clock. For instance, the 
serine-threonine kinase casein kinase 1 (CK1) phosphorylates PER and CRY which is vital for 
modulating circadian cycle length. The expression of other clock-controlled genes and output 
genes are modulated by the CLOCK/BMAL1 heterodimer, and a substantial fraction of genes in 
any particular cell or tissue have been found to undergo circadian oscillations (Takahashi, 2017; 
Zhang et al., 2014). Thus, disruption of circadian timing has profound implications. 
These molecular rhythms are not just expressed in the SCN, and work done in the R6/2 
mouse model shows that critical circadian rhythms of both core clock and clock-driven genes 
are abolished in vivo in peripheral organs such as the liver (Maywood et al., 2010). This 
deficiency is accompanied by the arrhythmic expression of the clock genes CRY1 and D site of 
albumin promoter (Albumin D-Box) binding protein (DBP), and a phase-advance in the PER2 
cycle. Functionally, this molecular timing system has a major impact on the expression of genes 
involved in metabolism throughout the body. For example, in peripheral tissues, including 
muscle, the metabolic genes pyruvate dehydrogenase kinase 4 (PDK4) and uncoupling protein 3 
(UCP3), are known to be positively regulated by the peroxisome proliferator activated receptor 
alpha (PPARα) (Dyar et al., 2018), which in turn displays a robust rhythmic expression in many 
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peripheral tissues and modulates BMAL1 expression by directly binding to the BMAL1 promoter 
(Canaple et al., 2006). Daily oscillations in the expression of the network of genes involved in 
mitochondrial lipid metabolism, including PDK4 and UCP3, are associated with oscillations in 
clock gene expression, with the peak during the rest or fasted phase, and REV-ERB-mediated 
repression of lipid mobilization and oxidation in anticipation of the active or feeding phase (de 
Goede et al., 2018a). Glucose levels are also known to exhibit diurnal rhythms. Glucose 
transporters 1 and 4 (GLUT1,4), responsible for basal blood to cytoplasm transport throughout 
the body and brain, and insulin-dependent transport primarily into adipose tissue and muscle, 
respectively, have a peak in expression level at the same time, suggesting increased systemic 
glucose transport and utilization with same-time diurnal variation (La Fleur et al., 1999). There 
is still much work to do to understand how transcriptional regulation by the molecular clock 
interacts with physiological mechanisms. The general assumption is that the temporal pattern of 
transcription favors adenosine triphosphate (ATP) production and energy utilization during the 
active phase while allowing remodeling and repair to dominate during rest (de Goede et al., 
2018b).  
The evidence that the molecular circadian clockwork is disturbed in HD is so far mixed, 
and more work is required to identify at what stage in disease progression these disruptions 
occur. For instance, we have previously reported that the circadian rhythms in PER2-driven 
bioluminescence were altered in the heart but not in the SCN in the BACHD (Whittaker et al., 
2018), while deficits in gene expression rhythms have been found in the SCN of the more 
severely impacted R6/2 model (Morton et al., 2005). There are still large gaps in our 
understanding of the critical rhythmic outputs impacted by the HD mutation, and thus, we 
consider this lack of knowledge a major deficiency in the literature as HD-driven alterations in 
circadian output could be an important clinical symptom of the disease.  
8 
 
HD is a neurodegenerative disease, and the most obvious cause of circadian disruption 
could be the loss of one or more cell populations in the SCN. HD patients exhibit a loss of SCN 
neurons by the end of life, with VIP-expressing cells being particularly vulnerable (van Wamelen 
et al., 2013). In prior work, we examined possible anatomical changes within the SCN of the 
BACHD mouse at 3-months of age, coinciding with the point when motor symptoms can first be 
measured. We found that in the BACHD male, but not the female, the SCN was smaller than in 
wild type (WT) mice. There were no differences in AVP or VIP expression within the SCN with 
genotype or sex (Kuljis et al., 2016). In the more severely impacted R6/2 mice, the SCN shows 
decreased expression of VIP and vasoactive intestinal peptide receptor 2 (VPAC2), its receptor 
(Fahrenkrug et al., 2007). Reductions in VIP would be expected to disrupt the population 
rhythms in neural activity within and from the SCN as this neuropeptide plays a key role not 
only in synchronizing SCN cell populations but also its outputs. For instance, VIP projections 
from the SCN are known to regulate the temporal patterns of activity in several major arousal 
centers including the orexin expressing cell population in the lateral hypothalamus. Notably, the 
expression levels of orexin are reduced in HD models (Kotliarova et al., 2005; Petersén et al., 
2005; Williams et al., 2011). Thus, in HD mouse models the expression of peptides and 
neuromodulators is altered in brain regions involved in the neural control of circadian rhythms 
without a significant loss of hypothalamic neurons. 
The circadian system is composed of cell-autonomous clock gene expression rhythms 
that are synchronized and adaptively phase aligned in tissues throughout the body by both a 
rhythmic output from the SCN and local or environmental signals (Mohawk et al., 2012). 
Individual SCN neurons express rhythms in spontaneous firing rate, with higher firing rates 
observed during the day and lower rates at night (Colwell, 2011; Webb et al., 2009). The 
BACHD and Q175 mouse models of HD exhibit decreased electrical activity in the SCN during 
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the day (Kudo et al., 2011a; Kuljis et al., 2018). This decrease in daytime firing in the SCN was 
not seen in the R6/2 model (Pallier et al., 2007) although firing rate deficits were seen in the 
orexin neurons, an SCN-driven output (Williams et al., 2011). Using electrophysiological 
techniques, our laboratory found that SCN neural activity rhythms were lost early in disease 
progression and were accompanied by loss of the normal daily variation in resting membrane 
potential in the mutant SCN neurons (Kuljis et al., 2018). The low neural activity could be 
transiently reversed by direct current injection, thus demonstrating that the neurons have the 
capacity to discharge at WT levels. Exploring the potassium currents known to regulate the 
electrical activity of SCN neurons, our most striking finding was that these cells in the mutants 
exhibited an enhancement in the large-conductance calcium- and voltage-activated potassium 
(BK) currents. The expression of the pore-forming subunit, potassium calcium-activated channel 
subfamily M alpha 1 (KCNMA1), of the BK channel was higher in the mutant SCN. These 
findings show that SCN neurons in the BACHD and Q175 models exhibit early pathophysiology 
and that dysregulation of BK current may be responsible. In humans, there is evidence that 
mHTT interacts with and impairs the function of a number of transcription factors, in particular 
the cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB) (Steffan 
et al., 2000; Sugars and Rubinsztein, 2003; Sugars et al., 2004), a known positive regulator of 
BK expression (Wang et al., 2009). 
Disorganized circadian timing leads to undesirable effects throughout the body (Colwell, 
2015), altering the function of key organ systems including the heart, pancreas, liver, lungs, as 
well as the brain. There is evidence that improving the sleep/wake cycle with sleep-inducing 
drugs (Kantor et al., 2016; Pallier et al., 2007), stimulants (Cuesta et al., 2012), bright light, 
and restricted wheel access (Cuesta et al., 2014) can ameliorate HD symptoms. Collectively, 
this prior research supports the hypotheses that circadian dysfunction interacts with HD 
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pathology leading to the exacerbation of HD-related symptoms and that circadian-based 
therapies can alter the trajectory of a genetically determined disease. The focus of my 
dissertation was to determine if circadian based treatments can be usefully applied to treat 
dysfunction in mouse models of HD. 
One of the most significant regulators of the circadian system is the daily feed/fast cycle 
(Bass and Takahashi, 2010; Tahara and Shibata, 2013). For example, SCN-lesioned animals can 
still be synchronized to a feeding schedule (Acosta-Galvan et al., 2011; Stephan, 2002; Tahara 
et al., 2012). Most of the published work has examined the consequences of placing the feeding 
in the daytime when it is misaligned with normal consumption patterns. However, there have 
been a few studies that found benefits in scheduling the feeding so that it was aligned with the 
normal activity cycle. Notably, the Panda lab has shown that healthy mice under time-restricted 
feeding (TRF) consume equivalent calories from a high fat diet as those with ad libitum (ad lib) 
access, display improved motor coordination, and are protected against obesity, 
hyperinsulinemia, and inflammation (Hatori et al., 2012). The TRF protocol was also beneficial 
in preventing age-induced cardiovascular dysfunction in Drosophila (Gill et al., 2015; Melkani 
and Panda, 2017). In the HD-N171-82Q mouse model, caloric restriction improved motor 
performance and survival while reducing cell death (Duan et al., 2003). Prior work in the R6/2 
mouse model showed that daytime scheduled feeding can restore HD-driven circadian gene 
expression in the liver (Maywood et al., 2010). Thus, TRF may represent a circadian-based 
therapy with the potential to alter the course of a genetic, neurodegenerative disease. 
The mechanisms through which TRF conveys benefits may result from a switch in 
bioenergetic pathways, specific responses to the timing and duration of feeding and fasting, 
and modulation of circadian rhythm timing and strength. Further, through food-anticipatory 
activity and reward behavior, TRF may strengthen and synchronize aspects of the circadian 
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system (Angeles-Castellanos et al., 2010; Astiz et al., 2019; Carneiro and Araujo, 2009; Colwell, 
2015), resulting in improved circadian alignment and enhanced signaling. These effects have 
relevance for HD pathology and symptoms, since normal HTT is found throughout the body and 
possesses many functional roles. These include trafficking of mitochondria (Reddy and 
Shirendeb, 2012), autophagosomes (Martin et al., 2015; Ochaba et al., 2014), and brain-
derived neurotrophic factor (BDNF) as well as its receptors (Gauthier et al., 2004; Liot et al., 
2013). Furthermore, HTT has anti-apoptotic properties (Rigamonti et al., 2000), and interacts 
with a number of transcriptional repressors and activators (Cattaneo et al., 2005). Importantly, 
HTT also promotes the production of BDNF (Zuccato et al., 2010). 
One mechanism through which TRF may convey benefits is by shifting the body into a 
state of elevated ketone body production and increasing serum ketone bodies, termed 
ketogenesis or ketosis. Manipulating the diet to achieve a state of heightened ketone body 
production has been used to treat epilepsy for nearly a century (Bailey et al., 2005). However, 
inducing ketosis as a therapy may come under criticism due to the association of ketone bodies 
with the pathologic state of ketoacidosis associated with Type-I diabetes. However, TRF, as well 
as ketogenic diets and application of exogenous ketone bodies, produces mild states of ketosis, 
with blood ketone levels rarely as high as 5 mM, whereas ketoacidosis occurs when blood 
ketones enter a range of 10 to over 25 mM. Further, central nervous system ketoacidosis has 
not been found to occur with diet (Al-Mudallal et al., 1996). 
Increasing the production of ketone bodies by the liver is dependent upon achieving a 
period during which glycogen stores are being depleted and fatty acids are being mobilized. 
Biochemically, carnitine-palmitoyl transferase 1a (CPT1A), a rate-limiting enzyme of fatty acid β-
oxidation, catalyzes the transfer of long-chain fatty acids from the outer to the inner 
mitochondrial membrane where they are liberated as acyl-CoA. This β-oxidation results in 
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acetyl-CoA that can either enter the Krebs or citric acid cycle, or be used by hydroxymethyl-
glutaryl CoA synthase 2 (HMGCS2) for the production of ketone bodies such as D-β-
hydroxybutyrate (βOHB). HMGCS2 is the fate committing enzyme in ketone body production. 
Importantly, CPT1A and HMGCS2, are expressed in a circadian regulated manner (Chavan et 
al., 2016). Once generated, ketone bodies have multiple fates. One fate of ketone bodies is 
transport to extrahepatic tissues where they are metabolized to generate ATP, with higher 
efficiency and lower production of reactive oxygen species (ROS) compared to glucose (Anton 
et al., 2018; Cahill, 2006; Veech et al., 2001). In addition to their role in bioenergetics, ketone 
bodies have other important roles and signaling functions which include enhancing 
mitochondrial respiration and attenuating oxidative stress (Milder et al., 2010; Tieu et al., 
2003), increasing BDNF expression (Duan et al., 2003), reducing inflammation (Guo et al., 
2018; Youm et al., 2015), functioning in epigenetic modification (Ruan and Crawford, 2018; 
Tognini et al., 2017), and signaling through G protein-coupled receptors (Offermanns and 
Schwaninger, 2015). 
Pathological changes in mitochondrial energy metabolism and ROS production occur in 
HD (Guedes-Dias et al., 2016; Siddiqui et al., 2012), and inducing ketosis may influence 
mitochondrial efficiency and decrease oxidative stress (Milder et al., 2010). Not surprisingly, 
BDNF levels are reduced in human HD patients and in mouse models of HD by as much as 80% 
compared to healthy controls, while BDNF levels are increased 3- to 4-fold in HD mice under 
feeding restriction (Duan et al., 2003; Ferrer et al., 2000).  
There is strong evidence for impairment in the clearance of mHTT in HD (Krainc, 2010), 
and reduction in mHTT levels through degradation has been shown to improve HD symptoms 
(Lee et al., 2015; Walter et al., 2016). Notably, signaling in the mammalian Target of 
Rapamycin (mTOR) molecule has been found to be altered in human TRF trials with 6-hr feed, 
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18-hr fast cycles (Jamshed et al., 2019), and this has important implications for cycles of repair 
and autophagy as well as mHTT proteolysis and clearance (Camberos-Luna et al., 2016). This is 
further highlighted by observations of alterations in cycling levels of markers of autophagy in 
mice, with an accompanying 20% reduction in mHTT, as well as an increase in mesenchymal 
stem and progenitor cells in mice and humans (Brandhorst et al., 2015; Ehrnhoefer et al., 
2018). These effects may be mediated by the switch to ketosis or the timing and duration of 
feeding and fasting, which can impact mTOR, proteolysis, and glymphatic clearance. 
Abnormal activation of microglia, the resident immune cells in the brain, occurs in HD 
patients (Sapp et al., 2001) and both macrophages and microglia express mHTT, which affects 
their function (Crotti et al., 2014). Once activated, microglia release inflammatory factors that 
are toxic to neurons and oligodendrocytes. Activated microglia have been found in the striatum, 
cerebral cortex, globus pallidus, and white matter of the brain from very early stages of the 
disease. Additionally, elevation of the pro-inflammatory cytokines TNF-α, IL-6 and IL-1β have 
been reported in both HD patients and mouse models (Björkqvist et al., 2008; Träger et al., 
2015). Through induction of ketosis and significant elevation of the ketone body βOHB, TRF 
may result in neuroprotection and reduction in inflammation (Guo et al., 2018; Offermanns and 
Schwaninger, 2015; Youm et al., 2015). 
As describe above, disturbances in the timing of the sleep/wake cycle are a well-
established symptom of HD that is also commonly present in other neurodegenerative diseases. 
These behavioral symptoms raise questions about the possible involvement of the circadian 
system. Using mouse models (Table 1), we have demonstrated behavioral and physiological 
circadian disruptions early in disease progression. Notably, these findings do not preclude the 
involvement of other structures involved in HD, such as the basal ganglia, in eliciting a 
disrupted circadian output. The dysfunction found in the circadian system of multiple HD 
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models does, however, raise the question of whether it is possible to ameliorate such symptoms 
and, in the end, to “treat” HD and other neurodegenerative diseases using environmental 
manipulations designed to improve circadian rhythms and enhance the sleep/wake cycle 
(Morton, 2013; Schroeder and Colwell, 2013). My dissertation work consisted of four studies all 
designed to determine whether core principles of circadian medicine could be used to reduce 
the symptoms in mouse models of HD. 
In HD patients, there is evidence that histaminergic signaling is disrupted and could 
contribute to abnormal rhythms in arousal (Shan et al., 2012; van Wamelen et al., 2011). 
Histamine (HA) is a neuromodulator whose levels vary with a daily rhythm, with peak release 
during the active cycle and lower levels during sleep. Histamine-3 receptors (H3R) are widely 
expressed in brain regions involved in cognitive processes and their activation promotes 
wakefulness (Lin et al., 2011; Parks et al., 2014). Thus, in my first study (Whittaker et al., 
2017), we sought to test the hypothesis that daily chronic treatment with a H3R antagonist 
would improve the non-motor symptoms early in the disease progression in the Q175 model. 
Homozygous (Hom) and Het Q175 mice received daily treatment in the early night (Zeitgeber 
Time (ZT) 13) with a H3R antagonist/inverse agonist (GSK189254) for one month. We 
evaluated the effect of the drug compared to vehicle controls on acute locomotor activity as 
well as on daily rhythms in activity and sleep behavior. In addition, we examined the impact of 
the treatment regime on the HD model’s performance in open field, T-maze, and tail suspension 
tests. Finally, as controls, we examined the impact of this treatment on motor performance and 
resident-intruder aggression. 
Because the daily feed/fast cycle is such a powerful regulator of the circadian system, in 
my second study (Wang et al., 2018), we sought to test the hypothesis that TRF (6-hr of 
feeding in the middle of the active phase followed by 18-hr fast) could improve the sleep/wake 
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cycle in the Q175 line. We examined the impact of imposing a regimen composed of 6-hr 
feeding aligned to the middle (ZT 15-21) of the period when mice are normally active (ZT 12-
24) followed by 18-hr of fasting. The treatment was applied to Q175 Hets starting when the 
mutants were 6 months of age and ending when they were 9 months of age. We selected this 
age range because this is when the Het Q175 start to show disrupted sleep/wake cycles and 
when motor symptoms are just beginning. Besides looking at the impact of TRF on rhythms in 
sleep and activity, we also measured the impact on motor symptoms, which are hallmark 
features of HD. Since HD patients experience an array of cardiovascular phenotypes, we used a 
telemetry system to test the hypothesis that TRF improves rhythms in core body temperature, 
heart rate, and heart rate variability driven by the autonomic nervous system. Finally, we 
determined whether TRF would alter the HD-driven transcriptional changes measured in the 
striatum and cortex of the Q175 line.  
In my third study (Whittaker et al., 2018), we sought to test the hypothesis that TRF (6-
hr feeding aligned to the middle of the active phase and 18-hr fasting) could improve the 
sleep/wake cycle in the BACHD line. We also evaluated the impact of the treatment on motor 
performance and autonomic function, and used a BACHD line expressing a PER2::LUCIFERASE 
(LUC) fusion protein as a bioluminescent circadian reporter to look at the impact of TRF on the 
amplitude and phase of clock gene expression. 
In my final study (Whittaker et al., in preparation), using the BACHD line, we sought to 
determine whether ketosis without TRF was sufficient to impart similar benefits to TRF in the 
treatment of HD. First, to test that TRF evokes a rhythm in ketone bodies and that the rhythmic 
increase in ketones persists for the full 3-months of treatment, the serum levels of ketones 
were measured across the 24-hr cycle in WT and mutant mice. Finally, we tested the hypothesis 
that a ketogenic diet could mimic the ketone rhythm observed under TRF and that the induction 
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of ketosis without TRF was sufficient to impart motor performance and sleep/wake rhythm 
benefits similar to those observed under TRF.  
Recent studies have raised the possibility that neuronal loss is accompanied by myelin 
breakdown in the striatum (both caudate and putamen) and in the corpus callosum early in the 
HD process (Bartzokis et al., 2007; Bourbon-Teles et al., 2019; Colwell and Ghiani, 2019). Using 
the BACHD mouse model, we have found evidence of axonal and myelin loss early in disease 
progression (3-months of age). In ongoing experiments, we are evaluating the impact of 3-
months of TRF on axonal and myelin loss, as well as on other markers of central pathology in 
HD. 
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Table 1-1: Summary of circadian phenotypes from mouse models of Huntington’s disease. 
Phenotype Models Citations 
Low amplitude 
activity rhythms 
R6/2, BACHD, 
Q175, HD 
rats, HD 
sheep 
(Balci et al., 2013; Bode et al., 2009; Kudo et al., 
2011a; Kuljis et al., 2016; Loh et al., 2013; Morton et 
al., 2005, 2014; Oakeshott et al., 2011)  
Hypoactivity during 
active phase 
BACHD, 
Q175, 
(Kudo et al., 2011a; Kuljis et al., 2016; Loh et al., 
2013; Morton et al., 2005) 
Hyperactivity 
during rest phase 
BACHD, Q175 (Kudo et al., 2011a; Kuljis et al., 2016; Loh et al., 
2013) 
Increase in cycle to 
cycle variation 
BACHD, Q175 (Kudo et al., 2011a; Kuljis et al., 2016; Loh et al., 
2013)  
Disrupted rhythms 
in sleep, sleep 
fragmentation 
R6/2, R6/1, 
Q175 
(Fisher et al., 2013, 2016; Kantor et al., 2013; 
Lebreton et al., 2015; Loh et al., 2013) 
Low amplitude 
rhythms in 
autonomic driven 
rhythms in heart 
rate, core body 
temperature. 
R6/1, R6/2, 
BACHD, Q175 
(Cutler et al., 2017; Kiriazis et al., 2012; Kudo et al., 
2011b; Mielcarek, 2015; Schroeder et al., 2016) 
Disrupted rhythms 
in hormones 
R6/2 (Dufour and McBride, 2016; Rudenko et al., 2019) 
Loss of melanopsin 
expressing retinal 
ganglia cells that 
carry light 
information to the 
central circadian 
clock (SCN) 
R6/2, N171-
82Q 
(Lin et al., 2019; Ouk et al., 2016) 
Disrupted rhythms 
in electrical activity 
in the SCN 
BACHD, Q175 (Kuljis et al., 2018, 2016) 
Disrupted gene 
expression rhythms 
in central clock 
R6/2 (Morton et al., 2005) 
Disrupted gene 
expression rhythms 
outside SCN 
R6/2 (Maywood et al., 2010; Morton et al., 2005) 
Pathology in central 
clock 
R6/2, BACHD (Fahrenkrug et al., 2007; Kuljis et al., 2016)  
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Figure 1: Figure 2-1: Serum concentrations of GSK189254 in Hom and Het Q175 mice.  
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Figure 2: Figure 2-2: Chronic administration of GSK189254 strengthened daily activity rhythms in 
Hom and Het Q175 mice.  
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Table 2: Table 2-1: Selected behavioral values for WT control mice.  
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Figure 3: Figure 2-3: Chronic administration of GSK189254 improved some aspects of the daily rhythm in 
cage locomotor activity in Hom and Het Q175 mice.  
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Figure 4: Figure 2-4: Chronic administration of GSK189254 alters the temporal pattern of sleep 
behavior in Q175 mice.  
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Figure 5: Figure 2-5: Chronic administration of GSK189254 improved exploratory behavior as 
measured by the open field test in Hom and Het Q175 mice.  
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Figure 6: Figure 2-6: Chronic administration of GSK189254 improved cognitive performance as 
measured by the T-maze in the Het Q175 mice.  
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Figure 7: Figure 2-7: Chronic administration of GSK189254 improved affect as measured by 
the tail suspension test in Hom Q175 mice.  
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Chapter 3: Time-restricted feeding improves circadian dysfunction as well as motor symptoms 
in the Q175 mouse model of Huntington’s disease 
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Figure 8: Chapter 3: Visual Abstract  
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Table 3: Table 3-1: List of distribution, statistical test, and power for each dataset analyzed in 
this study.  
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Figure 9: Figure 3-1: Locomotor activity rhythms were improved by the TRF regimen. 
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Table 4: Table 3-2: Comparisons of age-matched WT under ad lib conditions to Q175 mice under 
ad lib or TRF regimen.  
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Figure 10: Figure 3-2: TRF prevented disease-caused awakening time without altering the amount 
of sleep behavior.  
45 
 
Table 5: Table 3-3: Comparisons of age-matched WT under ad lib to regimen.  
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Figure 11: Figure 3-3: Autonomic output rhythms were improved by the TRF regimen.  
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Figure 12: Figure 3-4: TRF improved motor performance in the Q175 HD model. 
Table 6: Table 3-4: TRF improved motor performance in the Q175 HD model.  
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Figure 13: Figure 3-5: Altered expression level of multiple HD markers in the striatum of the Q175 
HD model. 
Table 7: Table 3-5: Top 10 canonical pathways and upregulators identified using IPA analysis in 
striatum of Q175 under TRF regimen.  
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Table 8: Table 3-6: Full dataset of expression of HD markers in the striatum of Q175 that are 
tested by using NanoString technology.  
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Figure 14: Figure 4-1: Locomotor activity rhythms were improved by the TRF regimen.  
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Table 9: Table 4-1: Rhythms in locomotor activity and sleep behavior in BACHD mice were 
improved by TRF.  
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Figure 15: Figure 4-2: Sleep behavior was altered by the TRF protocol.  
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Figure 16: Figure 4-3 Autonomic output rhythms from BACHD mice were improved by the TRF 
regimen.  
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Figure 17: Figure 4-4: TRF alters the peak phase, but not the amplitude, of the Per2::luC rhythms 
measured in peripheral organs in vivo.  
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Table 10: Table 4-2: TRF alters the peak phase but not the amplitude of the PER2::LUC rhythms 
measured in peripheral organs in the intact animal. 
Table 11: Table 4-3: TRF alters some aspects of the PER2::LUC rhythms measured in culture in a 
tissue-specific manner. 
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Figure 18: Figure 4-5: TRF improved motor performance in the BACHD model.  
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Table 12: Table 4-4: TRF improved motor performance in the BACHD model.  
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Figure 19. Figure 4-Supplemental figure 1: The temporal pattern of eating is altered in BACHD 
compared to WT controls.  
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Chapter 5: A ketogenic diet improves circadian dysfunction as well as motor 
symptoms in the BACHD mouse model of Huntington’s disease 
Introduction 
Huntington’s disease is a progressive neurodegenerative disease that imposes motor 
dysfunction accompanied by cognitive, psychiatric, and cardiovascular disturbance (Kuljis et al., 
2012; Margolis and Ross, 2003). HD is caused by a CAG trinucleotide repeat expansion within 
exon 1 of the Huntingtin (HTT) gene in excess of 35 CAG repeats. The CAG repeats are 
translated into abnormally long glutamine segments in the mutant Huntingtin protein (mHTT), 
leading to protein misfolding, soluble aggregates, and inclusion bodies detected throughout the 
body (Ciammola et al., 2006; Saft et al., 2005). The Huntingtin (HTT) protein is expressed 
throughout the body, with higher levels found in the brain than in the periphery. Further, brain 
regions with increased neuronal density are found to have higher HTT, with HTT expression 
being elevated in neurons versus glial cells (Li et al., 1993; Strong et al., 1993). 
Correspondingly, the mHTT protein is also more abundant in neurons than in glial cells with a 
similar distribution of aggregates (Bradford et al., 2010). While the loss of neurons in the 
striatum has been well characterized and is considered the hallmark of HD pathology, both gray 
and white matter loss have been well reported at different stages of HD progression (Bartzokis 
et al., 2007; Bourbon-Teles et al., 2019; Di Paola et al., 2012; Phillips et al., 2016), suggesting 
that the effects of myelin loss might be a significant factor in the disease course. 
The mHTT protein triggers dysfunction or loss in a wide range of cellular processes 
(Wright et al., 2017). Generally, the longer the CAG repeat, the greater the severity of the 
symptoms and the earlier the age of onset (Langbehn et al., 2010), with an average age of 
onset of motor symptoms and subsequent diagnosis around 40. Typically, mortality occurs 10 to 
20 years after the onset of initial motor symptoms, however, even among patients with the 
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same CAG repeat length, there is a significant range in the age of onset and severity of 
symptoms (Gusella et al., 2014; Wexler et al., 2004). Further, cognitive, affective, and other 
symptoms may arise up to two decades before the onset of motor symptoms (Paulsen, 2011; 
Paulsen et al., 2008). This variability supports the possibility that environmental modifiers can 
influence the disease, which suggests that appropriate and early disease management 
strategies can increase the health span and improve the quality of life of these patients. 
Therefore, it is vital to pursue this possibility as there are currently no treatments to prevent or 
delay the course of the disease. 
Sleep disorders are prevalent among HD patients and disruptions in sleep have 
detrimental effects on activities of daily living and the quality of life of patients and their 
caregivers (Morton et al., 2005; Cuturic et al., 2009; Aziz et al., 2010; Goodman et al., 2011). 
Mouse models of HD recapitulate the progressive and rapid breakdown of the circadian 
rest/activity cycle observed in human patients, which is typified by loss of consolidated sleep, 
increased wakeful activity during the rest (light) phase, and more sleep during the active (dark) 
phase (Morton et al., 2005; Kudo et al., 2011; Loh et al., 2013; Kuljis et al., 2016).  
Vigorous circadian rhythms are important to health and wellbeing, and disrupted 
circadian timing can lead to undesirable consequences throughout the body (Colwell, 2015), 
altering the function of key organ systems including the heart, pancreas, liver, lungs, as well as 
the brain. There is evidence that improving the sleep/wake cycle with sleep-inducing drugs 
(Kantor et al., 2016; Pallier et al., 2007), stimulants (Cuesta et al., 2012; Whittaker et al., 
2017), blue light therapy (Wang et al., 2017), bright light, and restricted wheel access (Cuesta 
et al., 2014) can ameliorate HD symptoms. Collectively, this body of research supports the 
hypotheses that circadian dysfunction interacts with HD pathology leading to the exacerbation 
78 
 
of HD-related symptoms and that circadian-based therapies can alter the trajectory of a 
genetically determined disease. 
One of the most significant regulators of the circadian system is the daily feed/fast cycle 
(Bass and Takahashi, 2010; Tahara and Shibata, 2013). Notably, SCN-lesioned animals can still 
be synchronized to a feeding schedule (Acosta-Galvan et al., 2011; Stephan, 2002; Tahara et 
al., 2012). Much of the published work investigating the consequences of TRF have done so by 
placing feeding during the rest phase when it is misaligned with normal feeding behaviors. 
However, a number of studies have investigated the effects of scheduling feeding aligned with 
normal activity and feeding behaviors. Notably, the Panda lab reported that healthy mice under 
a high-fat-diet TRF regimen consume equivalent calories as those with unrestricted or ad lib 
access, and that they display improved motor coordination and are protected against obesity, 
hyperinsulinemia, and inflammation (Hatori et al., 2012). In Drosophila, a TRF protocol was also 
beneficial in preventing age-induced cardiovascular dysfunction (Gill et al., 2015; Melkani and 
Panda, 2017). In HD-N171-82Q mice, feeding restriction increased BDNF levels 3- to 4-fold, 
improved motor performance and survival, and reduced cell death (Duan et al., 2003). Prior 
work in the R6/2 mouse model showed that daytime scheduled feeding can restore circadian 
rhythmicity, and reverse HD-driven impairment in the expression of circadian output genes in 
the liver (Maywood et al., 2010). We recently published results demonstrating that TRF (6-hr 
feeding aligned to the middle of the active phase and 18-hr fasting) could improve the 
sleep/wake cycle, motor performance, and autonomic function in the BACHD and Q175 lines 
(Wang et al., 2018; Whittaker et al., 2018). 
In recent human TRF trials utilizing 6-hr feed, 18-hr fast cycles, the diurnal pattern in 
cortisol and the expression of several circadian clock genes were altered, as were markers of 
autophagy, including pre-feeding increases in ketone bodies, the stress response and aging 
79 
 
gene sirtuin 1 (SIRT1), and the autophagy gene microtubule-associated protein 1 light chain 3 
(LC3A), and post feeding increases in mTOR and BDNF (Jamshed et al., 2019). This has 
important implications for improving circadian rhythms, cycles of repair and autophagy, as well 
as mHTT proteolysis and clearance (Camberos-Luna et al., 2016). This is further highlighted by 
studies with treatments that promoted alterations in cycling levels of markers of autophagy, 
with an accompanying 20% reduction in mHTT, as well as increases in mesenchymal stem and 
progenitor cells in mice and humans (Brandhorst et al., 2015; Ehrnhoefer et al., 2018). 
Reductions in the levels of mHTT by improved/stimulated autophagy/degradation have been 
shown to ameliorate HD symptoms (Lee et al., 2015; Walter et al., 2016). 
The mechanisms through which TRF conveys benefits have not been fully elucidated and 
may result from a switch in bioenergetic pathways, specific responses to the timing and 
duration of feeding and fasting, modulation of circadian rhythm timing and strength, and 
through food-anticipatory activity and reward behavior (Angeles-Castellanos et al., 2010; Astiz 
et al., 2019; Carneiro and Araujo, 2009; Colwell, 2015).  
One mechanism through which TRF may convey benefits is by shifting the body into a 
state of elevated ketone body production and increasing serum ketone bodies, called 
ketogenesis or ketosis. Increasing the production of ketone bodies by the liver is dependent 
upon achieving a period during which glycogen stores are being depleted, such as during 
starvation, fasting, and very low-carb, high-fat feeding. During these states, ketone bodies are 
generated at higher levels, regulated by the rate limiting enzymes CPT1A and HMGCS2, gating 
beta-oxidation and ketone body production respectively, which are both regulated in a circadian 
manner (Chavan et al., 2016).  
During ketogenesis, fat metabolism in the liver generates the ketone bodies βOHB, 
AcAc, and acetone which accumulate in the blood stream and result in ketosis. Acetone is 
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volatile and readily excreted in the breath. Ketone bodies are transported in the bloodstream to 
extrahepatic tissues where they have multiple fates (Achanta and Rae, 2017; Branco et al., 
2016; Newman and Verdin, 2014). βOHB and AcAc readily enter tissues and cross the blood–
brain barrier (BBB) through monocarboxylic transporters, which have also been identified in 
neurons and glia (Halestrap and Wilson, 2012; Pierre et al., 2000). One fate of ketone bodies is 
to be converted to acetyl CoA in mitochondria and enter the Krebs cycle at the level of citrate, 
bypassing glycolysis to generate ATP. Notably, this happens with higher efficiency and lower 
production of ROS compared to glucose (Anton et al., 2018; Cahill, 2006; Veech et al., 2001). 
While most of the βOHB that is used as an energy source in the brain is synthesized by the 
liver, ketone bodies also undergo synthesis and release by astrocytes (Guzmán and Blázquez, 
2004; Le Foll and Levin, 2016).  
In addition to their role in bioenergetics, ketone bodies have other important roles and 
signaling functions which include enhancing mitochondrial respiration and attenuating oxidative 
stress (Milder et al., 2010; Tieu et al., 2003), increasing BDNF expression (Duan et al., 2003; 
Ferrer et al., 2000), reducing inflammation (Guo et al., 2018; Youm et al., 2015), functioning in 
epigenetic modification (Ruan and Crawford, 2018), and signaling through G protein-coupled 
receptors (Offermanns and Schwaninger, 2015).  
All the above potential benefits have relevance for HD pathology and symptoms. For 
instance, due to the loss of functional HTT, BDNF levels are reduced in human HD patients and 
in mouse models of HD by as much as 80% compared to healthy controls (Ferrer et al., 2000; 
Gauthier et al., 2004) which is likely to have implications for neuronal survival. Additionally, 
pathological changes in mitochondrial energy metabolism and ROS production occur in HD 
(Guedes-Dias et al., 2016; Siddiqui et al., 2012). Further, there is strong evidence for 
impairment in the clearance of mHTT in HD (Krainc, 2010). Finally, abnormally activated 
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microglia, the resident immune cells in the brain, along with peripheral/invading macrophages 
are present in HD patients (Sapp et al., 2001). Both immune cell types express mHTT, affecting 
their function (Crotti et al., 2014). Together, these represent significant therapeutic targets in 
HD. 
Ketogenic approaches have been investigated in the treatment of other 
neurodegenerative diseases, including Alzheimer’s disease (Broom et al., 2019; Newman et al., 
2017; Ota et al., 2019; Roberts et al., 2017) and Parkinson’s disease (Jabre and Bejjani, 2006; 
Kashiwaya et al., 2000; Phillips et al., 2018). 
In this last study, using the BACHD line we sought to test the hypothesis that ketosis 
without TRF was sufficient to impart motor performance and sleep/wake rhythm benefits similar 
to those observed under TRF. To accomplish this, mice were placed on a custom low-
carbohydrate, high-fat diet rich in medium chain triglyceride (MCT) oils that are known to be 
rapidly metabolized in the liver (Brownlow et al., 2013).  
Materials and Methods 
The work presented in this study followed all guidelines and regulations of the UCLA 
Division of Animal Medicine that are consistent with the Animal Welfare Policy Statements and 
the recommendations of the Panel on Euthanasia of the American Veterinary Medical 
Association.  
Animals 
The BACHD mouse model that we used in this study expresses the full-length human 
mutant HTT gene encoding 97 glutamine repeats under the control of endogenous regulatory 
machinery (Gray et al., 2008). Female BACHD dams backcrossed on a C57BL/6J background 
(minimum 12 generations) were bred with C57BL/6J (WT) males from The Jackson Laboratory 
(Bar Harbor, Maine) in our own breeding facility to obtain male and female offspring, either WT 
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or heterozygous for the BACHD transgene. Data were also collected from WT mice from this 
colony. Only male mice were used in this study as there is a sex difference in the circadian and 
motor phenotypes (Kuljis et al., 2016). Genotyping was performed at 15 days of age by tail 
snips, and after weaning, littermates were group housed, until otherwise noted. All animals 
were housed in soundproof chambers with controlled lighting conditions, using a 12-hr light, 12-
hr dark cycle (12:12 LD, intensity 350 lux) for at least two-weeks prior to experimentation. For 
all experiments, a light meter (BK precision, Yorba Linda, CA) was used to measure light-
intensity (lux). The chambers were in the same animal housing facility with controlled 
temperature and humidity, and each chamber held 8 cages of mice, grouped together by 
feeding treatment. All animals received cotton nestlets, and water was made available at all 
times. Except where noted, mice were fed Teklad normal chow diet 7013 (NIH-31 Modified 
Open Formula Mouse/Rat sterilizable diet; Envigo, Madison, WI). 
This study used a total of 60 mice divided into 4 cohorts. The first group of BACHD (20) 
and WT (20) mice were placed on TRF or ad lib feeding and underwent around-the-clock 
ketone and glucose measurements. The second cohort of BACHD (10) and WT (10) mice were 
fed a ketogenic diet (KD) ad lib and measurements of ketones and behavior (sleep, activity, 
motor performance) were performed. Brain regions and peripheral tissues were collected from 
all cohorts for molecular and genetic experiments. 
Time-restricted feeding 
Mice were first entrained to a 12:12 LD cycle for a minimum of 2 weeks prior to any 
treatment. Experimental mice were housed in either normal cages or cages with a custom-made 
programmable food hopper that could temporally control access to food (NIH-31 diet; standard 
chow) and prevent food consumption during restricted times. Mice are coprophagic and were 
moved to new cages twice per week, as determined empirically to be the interval that 
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maintained very clean cages with low fecal count and visibly reduced coprophagic behavior 
during the fasting period. As mice were not moved to new cages between every daily feeding 
and fasting cycle, it is still possible that the mice consumed their own feces during the fast 
interval. The mice were held in these conditions from 3-months of age until collection.  
Ketogenic diet 
 KD treated mice had ad lib access to a custom ketogenic diet (see Supplemental figure 
1; Teklad custom diet TD.10911.PWD, Envigo, Madison, WI). Food consumption was measured, 
and food was renewed twice per week. Mice were fed the KD diet from 10 weeks of age. 
β-hydroxybutyrate and glucose measurements 
 Tail vein blood sampling was performed by making a small incision in the tail vein to 
permit repeat measures (under 3 µL per collection) with minimal pain and stress to the mice. 
Mice were retrieved from cages, placed on a stable surface and were minimally restrained by 
the tail at the time of collection. Blood sampling was performed under normal room lighting 
(350 lux) for testing ZT 0-12 and under dim-red-light conditions (3 lux) for testing ZT 12-24. 
Blood was tested for βOHB (1.5 µL sample). Glucose (0.6 µL sample) was measured at the 
same time as βOHB, when measured. Metabolite measurements were made using a 
commercially available glucose/ketone meter (Precision Xtra Blood Glucose and Ketone 
Monitoring System, Abbott Laboratories, Chicago, IL). Blood flow was stopped by applying 
pressure with sterile gauze to achieve hemostasis. 
Monitoring of cage locomotor activity  
Experimental mice were singly housed in cages with IR motion sensors and analyzed 
using the El Temps (A. Diez-Nogura, Barcelona, Spain; http://www.el-temps.com/principal.html) 
and ClockLab (Actimetrics, Wilmette, IL) programs. The locomotor activity was recorded as 
previously described (Wang et al., 2017). From before 3-months of age, mice were entrained to 
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a 12:12 LD cycle. Locomotor activity data were recorded using Mini Mitter (Bend, OR) data 
loggers in 3-min bins, and 7 to 10 days of data were averaged for analysis. We used the days of 
activity data collected just prior to the motor performance tests when the mice reached 6 
months of age. The data were analyzed to determine the period and rhythmic strength as 
previously described (Loh et al., 2013; Wang et al., 2017). The periodogram analysis uses a χ2 
test with a threshold of 0.001 significance, from which the amplitude of the periodicities is 
determined at the circadian harmonic to obtain the rhythm power. The amount of cage activity 
over a 24-hr period was averaged and reported here as the arbitrary units (a.u.)/hr. The 
number of activity bouts and the average length of bouts were determined using Clocklab, 
where each bout was counted when activity bouts were separated by a gap of 21 min 
(maximum gap: 21 min; threshold: 3 counts/min). The onset variability was determined using 
Clocklab by averaging the daily activity onset values. 
Monitoring of immobility-defined sleep behavior  
Immobility-defined sleep was determined as described previously (Loh et al., 2013; 
Wang et al., 2017). Mice were housed in see-through plastic cages containing bedding (without 
the addition of nesting material). A side-on view of each cage was obtained, with minimal 
occlusion by the food bin or water bottle, both of which were top-mounted. Cages were top lit 
using IR LED lights. Video capture was accomplished using surveillance cameras with visible 
light filters (Gadspot Inc., City of Industry, CA) connected to a video-capture card (Adlink 
Technology Inc., Irvine, CA) on a custom-built computer system. ANY-maze software (Stoelting 
Co., Wood Dale, IL) was used for automated tracking of mouse immobility.  
Immobility was registered when 95% of the area of the animal stayed immobile for 
more than 40 sec, as was previously determined to have 99% correlation with simultaneous 
EEG/EMG defined sleep (Fisher et al., 2012; Pack et al., 2007). Continuous tracking of the mice 
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was performed for a minimum of 5 sleep-wake cycles, with randomized visits (1-2 times/day) 
by the experimenter to confirm mouse health and video recording. The 3rd and 4th sleep-wake 
cycles were averaged for further analysis. Immobility-defined sleep data were exported in 1-min 
bins, and total sleep time was determined by summing the immobility durations in the rest 
phase (ZT 0-12) and active phase (ZT 12-24). An average waveform of hourly immobile-sleep 
over the two sleep-wake cycles was produced per genotype and treatment for graphical display. 
Variability of sleep onset, sleep offset, and sleep fragmentation was determined using Clocklab.  
Grip strength test 
 Grip strength testing was used to measure neuromuscular function as maximal muscle 
strength of forelimbs. The grip strength ergometer (Santa Cruz Biotechnology, Santa Cruz, CA) 
was set up on a flat surface with a mouse grid firmly secured in place. The grid was cleaned 
with 70% ethanol and allowed to dry before testing each cohort. Peak mode was selected to 
enable measurement of maximal strength exerted. The sensor is reset to zero before each trial. 
Well-handled mice were tested in their active phase under dim red light (3 Lux) and acclimated 
to the testing room for 10 minutes prior to testing. Mice underwent five trials with an inter-trial 
interval of at least two minutes. For each trial, each mouse was removed from its home cage by 
gripping the tail between the thumb and the forefinger. The mice are lowered slowly over the 
grid, and only their forepaws were allowed to grip the grid. Mice are pulled by the tail ensuring 
the torso remains horizontal until they are no longer able to grip the grid. Mice are then 
returned to their cages. The maximal grip strength value of each mouse is utilized. 
Rotarod test – accelerating version 
 The rotarod apparatus (Ugo Basile, Varese, Italy) is commonly used to measure motor 
coordination and balance. This apparatus consists of an axle or rod thick enough for a mouse to 
stand over the top of when it is not in motion and a flat platform a short distance below the 
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rod. The rod is covered with smooth rubber to provide traction while preventing the mice from 
clinging to the rod. In this study, mice were placed on top of the rubber-covered rod. When the 
mice moved at the pace set by the rotation rate of the rod, they would stay on top of it. When 
mice no longer moved at the selected pace, they dropped a short distance to the platform 
below. The time a mouse remains on the rod, before dropping to the platform is the latency to 
fall. Following a 15-min habituation to the testing room, mice were placed on the slowly 
rotating rod. The rod gradually accelerates from 5 rpm to 38 rpm over the course of the trial. 
The length of time the mouse stayed on the rod was recorded. A two-day protocol for the 
accelerating rotarod tests was used. On the first day, the mice were trained on the rotarod over 
5 trials. The maximum length of each trial was 600 sec, and mice were allowed to rest for a 
minimum of 60 sec between trials. On the second day, mice were tested on the rotarod and the 
latency to fall from the rotarod was recorded from 5 trials. Mice were again allowed to rest for a 
minimum of 60 sec between trials. Data from each mouse were analyzed after averaging the 
times from all 5 trials. The apparatus was cleaned with 70% alcohol and allowed to dry 
completely between cohorts. A dim-red-light (3 lux) was used for illumination during active 
(dark) phase testing.  
Statistical methods 
 We were interested in determining if ketones without TRF are sufficient to improve the 
symptoms in the BACHD mouse model, therefore, BACHD and WT ad lib KD-fed mice were 
compared to BACHD and WT ad lib normal chow-fed mice. The sample size per group was 
determined by both our empirical experience with the variability in the prior measures in the 
BACHD mice and a power analysis (SigmaPlot, SYSTAT Software, San Jose, CA) that assumed a 
power of 0.8 and an alpha of 0.05. To assess the impact of the treatments after 3-months, we 
applied a t-test and two-way analysis of variance for the analysis (2-way ANOVA) with genotype 
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and treatment as factors. To determine the impact of the treatment on temporal activity, sleep, 
and ketone waveforms, we used a two-way repeated measures analysis of variance (2-way RM 
ANOVA) with treatment and time as factors. Pairwise Multiple Comparison Procedures were 
made using the Holm-Sidak method. Correlations between circadian parameters and motor 
performance were examined by applying Pearson correlation analysis. Statistical analysis was 
performed using SigmaPlot. Data sets were examined for normality (Shapiro-Wilk test) and 
equal variance (Brown-Forsythe test). Between-group differences were determined significant if 
p < 0.05. All values are reported as group mean ± standard error of the mean (SEM). For each 
of the tests, we report the t- or F-values as well as the degrees of freedom. 
Results 
In these experiments, we examined the effect of KD on BACHD and WT mice. Treated 
mice were compared to normal chow diet controls. KD treated mice had ad lib access to a 
ketogenic diet from 3-months of age until collection. The body weights at the end of the study 
were different with the normal chow-fed mice being heavier than the KD-fed mice (not shown). 
The 2-way ANOVA found no effect of genotype (F(1,31) = 0.004, P = 0.949) but an effect of 
treatment (F(1,31) = 5.438, P = 0.027). Tail blood was sampled at 6 time-points throughout the 
24-hr cycle and ketones (βOHB) were measured. Both BACHD (n=8) and WT (n=8) exhibited 
clear rhythms in βOHB under KD-feeding but not under normal chow feeding conditions (Fig. 
5-1). βOHB levels in the BACHD exhibited significant effects of time (F(5, 107) = 20.443, P < 
0.001) and treatment (F(1, 107) = 76.599, P < 0.001). Post-hoc analysis by Multiple Comparison 
Procedures (Holm-Sidak method) indicated significant changes in βOHB levels were observed in 
BACHD under the KD at most phases (ZT 2, 6, 14, 18, and 22) of the daily cycle. In WT mice, 
βOHB levels exhibited significant effects of time (F(5, 107) = 8.833, P < 0.001) and treatment (F(1, 
107) = 16.267, P < 0.001). Post-hoc analysis indicated significant changes in βOHB levels in WT 
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mice elicited by the KD during the night (ZT 14, 18, 22). Therefore, both genotypes responded 
to the ad lib KD with the BACHD showing elevated βOHB at most phases while the WT mice 
exhibited elevated βOHB during the night. 
KD improved activity rhythms in the BACHD line. 
KD noticeably improved the temporal pattern of cage activity (Fig. 5-2). Both BACHD 
and WT (n=8 per group) exhibited clear rhythms in behavior under both the KD and the normal 
chow diet. Quantitative analysis of the activity rhythms of all 4 groups (2-way ANOVA) found 
that the power of the rhythms (Fig. 5-2A) were significantly altered by both genotype (F(1, 
31)=5.387, P = 0.028) and treatment (F(1, 31)=23.503, P < 0.001). The average amount of 
activity (Fig. 5-2B) varied with the genotype (F(1,31)=6.048, P = 0.020) but was not rescued by 
treatment (F(1,31)=0.074, P = 0.788). The % of activity in the day (Fig. 5-2C) surprisingly did 
not vary with genotype (F(1,31)=2.880, P = 0.101) but was improved by treatment 
(F(1,31)=37.388, P < 0.001). The variation in onset (Fig. 5-2D) was impacted by both genotype 
(F(1,31)=17.962 P < 0.001) and treatment (F(1,31)=8.232, P = 0.008). Overall, the mutants 
exhibited weaker rhythms than WT, and the KD improved all of the parameters. 
KD improved the temporal pattern of sleep behavior in the BACHD line. 
The amount of sleep is controlled by homeostatic mechanisms and appears to be largely 
unaltered by the KD. The total amount of sleep in a 24-hr cycle (Fig. 5-3A) was not altered by 
genotype (F(1, 31)= 0.018, P = 0.895) or treatment (F(1, 31)= 1.276, P = 0.268). Similarly, during 
their active (night) phase (Fig. 5-3B), there were no effects of genotype (F(1, 31)= 0.218, P = 
0.644) or treatment (F(1, 31)= 0.277, P = 0.603). During their rest (day) phase (Fig. 5-3C), 
there were effects of genotype (F(1, 31)= 8.841, P = 0.006) but no effect of the KD (F(1, 31)= 
1.524, P = 0.227). The untreated mutant mice exhibited less daytime sleep under normal chow 
feeding and this difference was no longer seen under the KD. Another key measure of sleep 
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quality is fragmentation or the number of sleeping bouts. The total number of sleep bouts in a 
24-hr cycle (Fig. 5-3D) was not altered by genotype (F(1, 31)= 0.284, P = 0.598) or treatment 
(F(1, 31)= 3.574, P = 0.069). During the day (ZT0-12), the number of sleep bouts was not altered 
by genotype (F(1, 31)= 0.001, P = 1.000) but was reduced by treatment (F(1, 31)= 7.724, P = 
0.010). There were not any corresponding changes during the night. Finally, the BACHD mice 
exhibited a phase delayed sleep onset that was corrected by the KD. The phase of sleep onset 
(Fig. 5-3E) was altered by genotype (F(1, 31)= 8.516, P = 0.007) but not treatment (F(1, 31)= 
2.487, P = 0.126). On average, the mutant mice on the normal chow diet started sleep at ZT 
1.6 ± 0.4 while the KD started sleeping at 0.2 ± 0.2 or closely aligned with lights-off (t(14) = 
2.924. P = 0.011, t-test). In summary, the KD increased daytime sleep and corrected the phase 
delay in sleep onset seen in the BACHD mice.  
KD improved motor function in the BACHD mice.  
The defining symptoms of HD are centered on motor dysfunction, thus, we hypothesized 
that KD would improve motor performance in the BACHD model. Motor performance in the 
BACHD was assessed using two well-defined tests: the accelerating rotarod and the grip 
strength tests (Fig. 5-4A, B). BACHD mice on the KD exhibited a longer latency to fall (t(14) = 
2.924, P = 0.005, t-test) off the rotarod compared to those on the normal chow diet. The 
performance on the rotarod (Fig. 5-4A) was influenced by genotype (F(1, 31) = 63.330, P < 
0.001) and treatment (F(1, 31)= 8.337, P = 0.007). Conversely, the decrease in grip strength was 
not improved in the mutants. The grip strength (Fig. 5-4B) varied with genotype (F(1, 31) = 
6.330, P = 0.015) but there was no effect of treatment (F(1, 31) = 0.249, P = 0.622). Overall, a 
key finding of this study is that rotarod performance in the BACHD model was improved by KD. 
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Discussion  
The present study demonstrates that a KD can ameliorate a range of symptoms linked 
to HD and related neurodegenerative disorders. Using the BACHD mouse model of HD, we 
showed that the KD boosted the amplitude and reduced variability in activity rhythms. The KD 
also corrected the phase delay in sleep onset seen in the BACHD mice although most sleep 
parameters were not altered by the diet. Finally, a key finding of this study is that the rotarod 
performance was improved by the KD. Thus, the KD successfully improved several behavioral 
and physiological parameters that have been shown to be compromised in HD. 
In this study, mice received ad lib access to a custom low-carbohydrate, adequate 
protein, high-fat diet rich in MCT oils that are known to be rapidly metabolized in the liver 
(Augustin et al., 2018; Brownlow et al., 2013). Under these dietary conditions, mice experience 
elevated ketone body production and a resulting increase in serum ketone bodies, a state 
referred to as ketogenesis or ketosis (Liu, 2008; McPherson and McEneny, 2012; Yeh and Zee, 
1976). Lipids entering the liver to undergo beta-oxidation are regulated by the rate limiting 
enzyme CPT1A. Following beta-oxidation, the liver generates ketone bodies through a process 
regulated by the rate limiting enzyme HMGCS2. Importantly, both enzymes are regulated in a 
circadian manner (Chavan et al., 2016). 
During ketogenesis, the ketone bodies βOHB, AcAc, and acetone are synthesized by the 
liver from fatty acids. Acetone volatilizes easily and is excreted in the breath. Ketone bodies are 
transported in the bloodstream to extrahepatic tissues where they have multiple fates (Achanta 
and Rae, 2017; Branco et al., 2016; Newman and Verdin, 2014). βOHB and AcAc readily enter 
extrahepatic tissues, including the brain. One fate of the ketone bodies is to be converted to 
acetyl CoA in mitochondria, after which they enter the Krebs cycle to generate ATP with high 
efficiency and with low production of ROS (Anton et al., 2018; Cahill, 2006; Veech et al., 2001). 
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Other important non-bioenergetic roles of Ketone bodies consist of signaling functions which 
include enhancing mitochondrial respiration and attenuating oxidative stress (Milder et al., 
2010; Tieu et al., 2003), increasing BDNF expression (Duan et al., 2003), reducing the 
activation and release of inflammatory mediators (Guo et al., 2018; Youm et al., 2015), 
functioning in chromatin remodeling and epigenetic modification (Ruan and Crawford, 2018; 
Tognini et al., 2017), and signaling through G protein-coupled receptors to induce a 
neuroprotective phenotype in monocytes and/or macrophages (Offermanns and Schwaninger, 
2015). 
In this study, we showed that under ad lib KD conditions, the levels of βOHB are 
strongly rhythmic (Fig. 5-1). All of the KD treated mice (BACHD, WT) exhibited clear rhythms 
in ketones, while those under normal chow feeding conditions did not (Fig. 5-1). The KD-fed 
mutants, but not the KD-fed WT, showed higher levels of ketones during the early day, taking 
longer to resolve βOHB levels below 0.5 mM. Therefore, both genotypes responded to the KD 
with the BACHD showing elevated ketones at most phases while the WT exhibited elevated 
ketones during the night. One prior study has also shown that KD induces serum and intestinal 
βOHB levels to robustly oscillate in a circadian manner, an event coupled to tissue-specific cyclic 
histone deacetylase (HDAC) activity and histone acetylation (Tognini et al., 2017). This was 
complemented by another study where KD shifted the phase of Bdnf transcript expression in 
the liver and brain and increased protein levels in the brain (Genzer et al., 2016).  
The ad lib fed KD noticeably improved the temporal pattern of cage activity (Fig. 5-2). 
This regimen increased the power of the rhythms as well as reduced the inappropriate activity 
in the day and the variability in onset. Some the benefits were only observed in the mutant 
mice and not in the WT, including the improvement in power, increase in activity, and reduction 
in onset variability. Interestingly, the reduction of activity during the rest cycle was seen in both 
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genotypes. Prior work using scheduled feeding protocols also improved locomotor activity 
rhythms in several mouse models of HD, including the R6/2 (Skillings et al., 2014), Q175 (Wang 
et al., 2018) and BACHD (Whittaker et al., 2018) lines. These improvements in the locomotor 
activity rhythms under TRF could be driven by the nightly increase in ketones observed in the 
present study. We could only find one other study that examined the impact of ad lib KD-
feeding on locomotor rhythms (Genzer et al., 2015), which reported improvements in nocturnal 
activity levels in WT mice. 
The amount of sleep is controlled by homeostatic mechanisms and was largely unaltered 
by the KD (Fig. 5-3). We did see some evidence that the KD improved daytime sleep and 
reduced fragmentation during this phase. In addition, a striking improvement in the onset of 
sleeping was observed in the mutant mice, which likely has more to do with circadian regulation 
than sleep homeostatic mechanisms. Variability in sleep onset has been associated with 
decreased academic performance and reduced white matter in humans (Fuligni et al., 2018; 
Telzer et al., 2015), thus improvements in precision of sleep onset are an important target for 
therapeutic interventions. Prior work with the R6/2 (Fisher et al., 2013; Kantor et al., 2013) and 
Q175 (Fisher et al., 2016) mouse models has provided evidence of dysfunction in 
electroencephalogram (EEG) defined sleep including increases in sleep fragmentation as well as 
characteristic changes in the EEG spectral profiles. Total amount of non-rapid eye movement 
(NREM) and rapid eye movement (REM) sleep over 24-hrs as well as homeostatic responses to 
sleep loss were not impacted by the mutation (Fisher et al., 2016). 
There is a rich literature linking energy metabolism and sleep homeostasis. The ketone 
bodies AcAc and βOHB, generated from the breakdown of fatty acids, are major metabolic fuels 
for the brain, especially under conditions of low glucose availability. Ketogenesis is modulated 
by the activity of PPARα, and treatment with a PPAR activator has been shown to induce a 
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marked increase in plasma AcAc and βOHB in mice, accompanied by increased slow-wave 
activity during NREM sleep (Chikahisa et al., 2014). This study also reported that sleep 
deprivation increased mRNA expression of ketogenic genes such as PPARα and HMGCS2 in the 
brain and decreased ketolytic enzymes such as succinyl-CoA:3-oxoacid CoA transferase (SCOT).  
In humans, there has been a fair amount of work exploring the links between use of the 
KD and sleep in the context of epilepsy. Many patients exhibit epileptic discharges during sleep 
and the KD is one of the few non-pharmacological approaches that helps to reduce seizures. 
Reviews of this work consistently find support for the hypothesis that KD-feeding impacts sleep 
architecture [e.g. (Jain and Glauser, 2014)], with several reports of KD-feeding improving sleep 
in epileptic and type 2 diabetes patients (Siegmann et al., 2019). Therefore, there are good 
reasons to explore the impact of the KD on sleep architecture in the BACHD model. 
The BACHD mouse model shows alterations in the temporal patterning of neural activity 
recorded in the SCN (Kudo et al., 2011a; Kuljis et al., 2016). The weakening of the electrical 
output of the SCN would be expected to impact the phase of peripheral molecular clocks that 
are driven by the SCN. In the R6/2 model of HD, circadian rhythms of PER2 bioluminescence 
were normal in the SCN but phase advanced in the liver (Maywood et al., 2010). One of the 
weaknesses of this study is that we have not evaluated the impact of the KD on the circadian 
system in the BACHD. Specifically, we need to determine if the ad lib KD improves circadian 
rhythms measured under constant darkness. In addition, using our BACHD PER2::LUC mice, the 
impact of KD should be evaluated on circadian rhythms in bioluminescence measured from the 
SCN and peripheral organs like the liver. In prior work (Whittaker et al., 2018), we did not see 
any evidence for genotypic differences between the clock gene expression in WT and BACHD 
mice. Still the TRF protocol shifted the phase of the rhythm in peripheral organs but not in the 
SCN. We expect similar results with the ad lib KD, i.e. the phase of peripheral rhythms but not 
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the SCN will be altered by the diet. Prior work shows that feeding schedules can shift the phase 
of the rhythms in clock gene expression throughout the body including in limbic structures 
involved in motivation and reward (Angeles-Castellanos et al., 2007; Waddington Lamont et al., 
2007) as well as in the hypothalamus (Akiyama et al., 2004). 
A prior study (Genzer et al., 2015) examined the effect of ad lib KD-feeding on 
locomotor activity, clock gene expression, and average daily levels of 5' adenosine 
monophosphate-activated protein kinase (AMPK), mTOR, and SIRT1 for two months, compared 
to a low-fat diet (LFD) in WT mice. The KD resulted in increased basal levels of locomotor 
activity during the dark and light periods. Additionally, the KD led to a 1.5-fold increase in the 
levels of blood glucose and insulin. In the brain, the phosphorylated-AMPK/AMPK ratio was 40% 
higher under KD, whereas in the liver it was not affected. Notably, Phosphorylated-AMPK 
induces the degradation of PER and CRY proteins, leading to phase advances in the clock. The 
KD led to 40% and 20% down-regulation of the ratio of phosphorylated-P70S6K/P70S6K, in the 
brain and liver, respectively. P70S6K is a downstream target of mTOR, which was also 
decreased. SIRT1 levels were 40% higher in the brain, but 40% lower in the liver of KD-fed 
mice. Clock genes showed delayed rhythms under the KD. Importantly, in the brain of KD-fed 
mice, amplitudes of clock genes were down-regulated, whereas a 6-fold up-regulation was 
found in the liver. It should be noted that mice were fasted 12 or more hours before collection, 
which was indicated by the elevated ketones in the non-ketogenic LFD fed mice at collection 
(Genzer et al., 2015) which complicates interpretation of this data. Another important study 
from the Sassone-Corsi laboratory (Tognini et al., 2017) found that a KD had profound and 
differential effects on liver and intestine clocks. Specifically, the amplitude of clock-controlled 
genes and BMAL1 chromatin recruitment were drastically altered by a KD in the liver, but not in 
the intestine. The KD induced nuclear accumulation of PPARα in both tissues but with a 
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different circadian phase. Also, gut and liver clocks responded differently to carbohydrate 
supplementation during KD-feeding. This data indicates that the metabolic state under a KD 
reduced satiety and, in the liver, reduced anabolism along with increased gluconeogenesis. 
These changes may well be beneficial to patients with HD as well as those with other 
neurodegenerative diseases. 
HD is defined as a movement disorder, as the most striking and debilitating symptoms 
include motor deficits. Critically, the KD improved performance of the HD mutant mice on at 
least one motor test (Fig. 5-4). In contrast, the grip strength was not improved by the 
treatment. In prior work, aged mice on a cyclic, ad lib fed KD did not show improvement in 
motor strength tests (Newman et al., 2017), while those on a defined daily caloric intake from a 
KD did improve in motor strength tests (Roberts et al., 2017). Further, scheduled feeding has 
been found to improve motor function in the Q175 (Wang et al., 2018) and BACHD models 
(Whittaker et al., 2018), as well as the exploratory behavior in the open field (Skillings et al., 
2014) in the R6/2 model. Notably, marginal improvement in motor performance has been 
reported in other mouse disease models treated with a KD (Ari et al., 2014; Brownlow et al., 
2013).  
Another key symptom of HD is the loss of neurons in the striatum. At the ages we have 
been working with the BACHD, there is no obvious neuronal loss, although we have evidence 
that these mutants begin to present signs of axonal degeneration, loss of myelin, and 
inflammation at early ages (See Chapter 6). We have collected the tissue from the mice used in 
this study and are determining whether the KD ameliorates some of these histopathological 
features. 
Approaches directed at boosting circadian output have shown efficacy for improving 
outcomes in different HD mouse models. There is evidence that improving the sleep/wake cycle 
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with sleep-inducing drugs (Kantor et al., 2016; Pallier et al., 2007), stimulants (Cuesta et al., 
2012; Whittaker et al., 2017), bright light & restricted wheel access (Cuesta et al., 2014), 
enhanced blue light (Wang et al., 2017), and scheduled feeding (Wang et al., 2018; Whittaker 
et al., 2018) can improve HD symptoms. This body of work supports the general hypothesis 
(Longo and Panda, 2016; Morton, 2013; Schroeder and Colwell, 2013; van Wamelen et al., 
2015) that circadian-based therapies can alter the trajectory of a genetically determined 
disease.  
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Figure 20: Figure 5-1: TRF and KD evoke daily rhythms in serum ketones (βOHB). 
(A) Schematic of experimental design. Mice were held in 12:12 LD cycle so the time of lights-on 
is ZT 0 and the time of lights-off is ZT 12. LD cycle is represented by light-dark bars. (B) Tail 
vein blood was collected at 6 time points for BACHD (diamonds) and WT (circles) mice under ad 
lib (grey) and TRF (green). Green shading represents the feeding period. (C) Tail vein blood 
was collected at 6 time points for BACHD (diamonds) and WT (circles) mice under ad lib (grey) 
and KD (blue). The symbols show group mean with SEM plotted. Comparisons between the 
mice of each genotype were made with two-way ANOVA for repeated measures with time and 
treatment as factors. Asterisks represent significant differences due to KD compared to the ad 
lib controls, number signs represent significant differences due to time (P < 0.05; n = 8 per 
group). 
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Figure 21: Figure 5-2: Locomotor activity rhythms were improved by the KD. 
(A) The strength of the activity rhythm is indicated by the power (% variance) of the χ2 
periodogram analysis. (B) Average hourly activity levels from 7-10 days of cage activity. (C) 
The % of total activity that occurred in the daytime (rest) phase. (D) The averaged onset 
variability was calculated from the best-fit regression line. For this and other figures, the vertical 
bar plots show group means and SEM while the symbols show the values from individual 
animals in each group (BACHD ad lib, grey diamonds; BACHD KD, blue diamonds, WT ad lib, 
grey circles; WT KD, blue circles). Comparisons between cohorts were made using a 2-way 
ANOVA with genotype and treatment as factors. Asterisks represent significant differences (P < 
0.05) by two-way ANOVA due to treatment while number sign represents significant differences 
due to genotype. 
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Figure 22: Figure 5-3: Sleep behavior was altered by the KD. 
Video recording in combination with automated mouse tracking analysis software was used to 
measure immobility-defined sleep (n = 8 per group). (A) Total sleep in the 24-hr cycle while 
amount of sleep in night (B) and day (C) are plotted. (D) Sleep fragmentation is defined as 
the number of sleep bouts in the 24-hr cycle. (E) the phase (ZT) of sleep onset is shown. 
Comparisons between cohorts were made using a 2-way ANOVA with genotype and treatment 
as factors. Asterisks represent significant differences (P < 0.05) by two-way ANOVA due to 
treatment while number sign represents significant differences due to genotype. The double 
dagger represents significant differences (P < 0.05) by t-test. 
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Figure 23: Figure 5-4: KD improved motor performance in the BACHD model. 
(A) The accelerating rotarod test measures time on the rod until the mice fall. Improvements in 
motor performance are shown by longer latency to fall. (B) Grip strength measurements. 
Comparisons between cohorts were made using a 2-way ANOVA with genotype and treatment 
as factors. Asterisks represent significant differences (P < 0.05) by two-way ANOVA due to 
treatment while number sign represents significant differences due to genotype. The double 
dagger represents significant differences (P < 0.05) by t-test. 
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Figure 24: Figure 5-Supplemental figure 1: Comparison of NIH-31 standard chow diet 
with KD. 
The KD is a custom very-low-carbohydrate, adequate protein, high-fat diet rich in MCT oils. The 
KD diet was modified from a stock Teklad KD diet from Envigo. The modified KD removed 
sources of carbohydrates and added MCT oil in order to better generate ketosis. The KD has 
~50% more calories per gram compared to NIH-31. 
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Chapter 6: Conclusions 
In these studies, I sought to test the hypotheses that circadian dysfunction interacts 
with HD pathology leading to the exacerbation of HD-related symptoms and that circadian-
based therapies can alter the trajectory of a genetically determined disease.  
In the first study, we sought to determine if the daily administration of the H3R 
antagonist/inverse agonist GSK189254 would improve nonmotor symptoms in the Q175 mouse 
model of HD. Several previous studies support a role for H3R in promoting wakefulness and for 
HA as a potent regulator of the circadian system (Cote and Harrington, 1993; Eaton et al., 
1995; Haas and Panula, 2003; Jacobs et al., 2000; Kim et al., 2015; Lin et al., 2011; Parmentier 
et al., 2002; Watanabe et al., 1984). For three months, starting at ages before the onset of 
motor symptoms in Hom and Het Q175 mice, we administered GSK189254 nightly at a time 
when HA levels would normally be rising. We found that this treatment improved daily activity 
rhythms and produced short‐term changes in daily sleep behavior while not altering the overall 
amount of sleep in a 24‐hr cycle. Further, GSK189254 treatment improved exploratory behavior, 
cognitive performance, and mood without increasing anxiety‐like behavior. Our findings suggest 
that drugs targeting the H3R system may benefit somnolence and arousal in the management 
of HD.  
In the second study, we placed Het Q175 mice on TRF for three months starting at an 
age before the onset of motor symptoms. We found that the TRF regimen improved the daily 
activity rhythms and advanced the time that the mice ended their sleep phase without changes 
in total amount of sleep in each 24‐hr cycle. Additionally, the TRF regimen improved motor 
performance. Markedly, we found that the improved circadian behavior was correlated with 
improved motor function in the TRF group, suggesting that improved circadian timing underlies 
the improved motor function in the treated mice. Cardiovascular events are a major cause of 
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death in the HD population (Lanska et al., 1988; Sørensen and Fenger, 1992), and we found 
that TRF improved cardiovascular performance, including increased HRV. Notably, decreased 
HRV, generally considered an indication of poor cardiovascular health and a predictor for 
cardiovascular disease and mortality (Thayer et al., 2010), has been reported in HD patients 
beginning during the pre-symptomatic stage of disease progression (Andrich et al., 2002; Aziz 
et al., 2010b). To our knowledge, this is the first study showing that a TRF regimen can 
improve HRV in a disease model.  
Furthermore, we reported an analysis of the Q175 striatum using NanoString technology 
in which over 50% of the genes shown to be downregulated in Q175 controls (Langfelder et al., 
2016) were upregulated by TRF. We then looked at the top upregulated factors of canonical 
pathways identified using IPA analysis. Three were neurotrophic factors, including BDNF, which 
is reduced in human HD patients and in mouse models of HD (Duan et al., 2003; Ferrer et al., 
2000). Additionally, we identified CREB1, also reduced in HD patients (Steffan et al., 2000; 
Sugars and Rubinsztein, 2003; Sugars et al., 2004), as well as a demthylase, tet methylcytosine 
dioxygenase 1 (TET1), which has been reported to upregulate several neuronal memory-
associated genes and impair contextual fear memory (Kaas et al., 2013). 
In the third study, we kept BACHD mice on a TRF regimen for three months starting at 
an age before the onset of motor symptoms. We found that TRF boosted the amplitude and 
reduced variability in activity rhythms, and that the temporal patterning of both sleep behavior 
and sleep fragmentation were improved. Physiologically, TRF increased HRV during sleep and 
increased the amplitude of the HR rhythm. We found that BACHD still exhibit robust peripheral 
PER2::LUC rhythms and that TRF was sufficient to modify the phase but not the amplitude of 
the rhythms. Further, motor performance in the BACHD was improved by TRF. As in the Q175, 
we observed a correlation between improved circadian behavior and improved motor function in 
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the TRF group, further supporting that improved circadian timing underlies the improvements 
observed in motor function.  
In the final study, we first determined that TRF induced robust rhythms in serum levels 
of βOHB in both BACHD and WT mice. While this work is still ongoing, the behavioral data has 
been collected and analyzed. We found that an ad lib fed KD evoked robust rhythms in serum 
levels of βOHB in both genotypes, although daytime levels of ketones were only elevated in the 
mutants. The KD did not alter total behavioral sleep, night-time sleep or total sleep 
fragmentation, however it did increase daytime sleep as well as improve the timing of sleep 
onset in the mutant mice. Additionally, improved activity rhythms, including rhythmic power, 
average activity levels, as well as reduced inappropriate daytime activity and onset variability 
were observed. Notably, the KD improved the performance of the mutants on the rotarod but 
not the grip strength. Finally, we have collected tissue to determine if the KD or TRF alter core 
pathology in the striatum of the BACHD mice. We have found evidence that the striatum of 3-
month-old male BACHD mice, under ad lib normal chow feeding conditions, begin to present 
signs of axonal degeneration and reduction in myelination, accompanied by inflammation and 
astrogliosis, as suggested by major histocompatibility complex class II (MHCII) and glial 
fibrillary acid protein (GFAP) expression (Fig. 6). Future work will determine if KD or TRF alter 
these pathological markers. 
Taken together, these studies support the use of circadian approaches in delaying 
progression and improving quality of life of HD patients as well as other neurodegenerative 
disorders with similar biology. It should be emphasized that these circadian treatments were 
applied at early symptomatic stages of the disease. In progressive degenerative diseases and 
especially in genetic diseases such as HD, our data is consistent with recommendations of early 
genetic testing and use of circadian based therapeutic approaches. 
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There may be some concerns about using a TRF protocol in HD populations because of 
the low body weights associated with the disease progression. It has been reported that HD 
patients with a higher body mass index (BMI) in early-stage HD have a slower progression of 
disease (Costa de Miranda et al., 2019; Myers et al., 1991). Additionally, increased leptin 
production has been reported in HD patients which could suppress hunger (Aziz et al., 2010c), 
and early-stage impairment in energy balance and higher sedentary energy expenditure are 
also seen in the patients (Gaba et al., 2005; Pratley et al., 2000). This all culminates in 
progressive weight loss, a well-documented component of pathology in HD patients (Djoussé et 
al., 2002; Hamilton et al., 2004; Sanberg et al., 1981). However, and most importantly, TRF did 
not result in weight loss in our studies. Mice under TRF consumed the same volume of food as 
the ad lib fed normal chow mice, and the body weights of TRF fed HD mice remained 
comparable to WT mice (Wang et al., 2018; Whittaker et al., 2018). Similarly, the KD diet 
resulted in a small increase in bodyweight in the WT and a small decrease in bodyweight in the 
BACHD over the three months of the trial (Chap. 5), and neither of these changes was 
significant. A reduction in food consumption or bodyweight would have introduced confounding 
variables. However, it has been previously reported in WT mice that TRF with normal chow can 
reduce fat mass and increase lean mass while not significantly impacting overall body mass 
when compared to ad lib feeding with normal chow (Chaix et al., 2014). 
 Altogether, these findings support the hypothesis that early interventions that improve 
sleep/wake timing and circadian rhythmicity will reduce HD symptoms; however, there remain 
important gaps in our knowledge. Although we have strong evidence of axonal and myelin loss 
early in the striatum, motor cortex, and corpus collosum in male BACHD mice (unpublished), we 
have not yet determined whether TRF or the KD alter central aspects of the pathology. Prior 
work in the R6/2 model found that rhythms in mPer2 gene expression were globally 
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downregulated throughout the brain and that peak/trough differences were lost. However, 
PER2::LUC bioluminescence expression in the R6/2 SCN revealed that intrinsic pace-making 
mechanisms remained intact (Maywood et al., 2010). On the other hand, these mutants were 
reported to have disrupted circadian function with phase advanced mPer2 and arrhythmic Dbp 
in the liver, which were restored by TRF. In the same mice, Pk2 mRNA in the SCN 
demonstrated progressive reduction in expression, while in WT mice, Pk2 is high during 
circadian daytime and low at night. The product of Pk2 is proposed to suppress daytime activity 
in nocturnal rodents (Cheng et al., 2002; Prosser et al., 2007). Notably, Pk2 is a transcriptional 
target of BMAL1, which was also found to be disrupted in R6/2 mice (Morton et al., 2005). The 
central impact of TRF or the KD on rhythmic outputs has not yet been examined and is an 
important gap in our knowledge. Furthermore, we do not know the impact of the BACHD 
mutation on rhythmic outputs in gene expression and would also like to address whether 
rhythms in corticosterone and cytokines are altered in serum, and if so, determine if TRF or the 
KD are able to repristinate them. 
The mechanisms through which TRF and the KD convey benefits are uncertain and may 
be mediated by multiple pathways. Both likely interact with various molecular clocks in the 
body, including the liver clock, and this may be an important aspect of the benefits. While we 
showed that TRF can alter the phase of some peripheral rhythms, it is also important to 
determine if KD can exert similar effects on peripheral rhythms, as well as ascertain whether 
TRF and KD can alter the phase and amplitude of molecular clock driven outputs. Finally, it 
must be established whether the KD can exert benefits similar to those elicited by TRF in the 
improvement of autonomic parameters. 
 Future directions of our work comprise determining if the BACHD mutation disrupts 
rhythms in gene expression and if these rhythms are altered by TRF and the KD, thus we 
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collected striatum, cortex, and hypothalamus, as well as peripheral organs and serum, from WT 
and BACHD mice under TRF and ad lib fed normal chow in a 4-hr interval time-course. Based 
upon TRF data shared with us from the laboratory of Satchin Panda (unpublished), some of the 
key genes to consider in this follow-up work include a) circadian clock genes Per2, Bmal1, 
Npas2, Nrld2; b) clock controlled genes Pk2, Avp, Ppara, Ppargcla; c) transcriptional related 
genes Creb1, Fos, Arc, Erg4; d) metabolism related genes Ppargc1A, Sirt1, Parp1, Prkaa1, Mtor; 
d) autophagy related genes Bnip3, Dram1; e) HD related genes Htt, Kcnab1, Homer1a, Bdnf. 
 Following on our findings of early signs of axonal and myelin loss in brain regions in 3-
month-old male BACHD mice, it is important to examine the impact of TRF or the KD on central 
aspects of pathology. Using Western blot and immunohistochemistry [as described in (Lee et 
al., 2018); Fig. 6; Table 6-1], we observed clear early signs of axonal and myelin loss in the 
striatum, as evidenced by increased expression of non-phosphorylated neurofilament (NF)-H 
(SMI-32), a marker suggestive of axonal degeneration, accompanied by decreased expression 
of axonal and myelin markers NF-160 and myelin basic protein (MBP), respectively (Fig. 6-1). 
These abnormalities were accompanied by elevated expression of GFAP, an astrocytic marker, 
and of MHCII, suggesting astroglial activation and a concurrent immune response in the brain 
parenchyma (Fig. 6-2). MHCII was expressed by the astrocytes and other cells in what appear 
to be blood vessels, possibly implicating immune cells recruited from the periphery. This 
observation is currently under further investigation to better define these cell types. Bizarrely, 
we did not observe altered expression of ionized calcium binding adaptor molecule 1 (Iba-1), a 
microglia marker, or evidence of co-expression of MCHII and Iba-1. These findings are 
supported by reports of astrocytic dysfunction (Hsiao et al., 2013; Khakh et al., 2017), as well 
as cerebral vasculature alterations and BBB leakage in HD patients and mouse models of HD (Di 
Pardo et al., 2017; Drouin-Ouellet et al., 2015; Lim et al., 2017). However, it will be important 
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to establish what cell types are expressing MHCII and if they are recruited from the periphery at 
this early stage of disease (Konishi et al., 2017). 
Abnormal and deficient neural cell development and adult neurogenesis have been 
reported in autopsied human HD brains and animal models of HD (HD iPSC Consortium, 2017). 
We have preliminary evidence of persisting oligodendrocyte progenitors in the male BACHD 
striatum as shown by nuclear expression of glutathione S-transferase pi (GSTπ; not shown). 
Although preliminary, this finding is encouraging as TRF may promote maturation of progenitor 
cells committed to the oligodendrocyte lineage to support early repair and restoration of myelin 
(Boulanger and Messier, 2014). 
In conclusion, we show that early-stage arousal promoting substances such as H3R 
antagonists, and dietary approaches such as TRF or a KD can ameliorate a range of symptoms 
of HD and related neurodegenerative disorders. These studies add to a growing body of 
evidence showing that enhancements in “circadian hygiene” lead to improvements in health 
outcomes for a wide range of human diseases including neurodegenerative disorders.  
110 
 
Figure 25: Figure 6-1: Western blot and 
immunohistochemistry in BACHD brains show axonal and 
myelin loss early in disease progression. 
Figure 26: Figure 6-2: Western blot and immunohistochemistry 
in BACHD brains suggests astroglial activation and a 
concurrent immune response in the brain.  
Figure 6-2: Western blot and immunohistochemistry in 
BACHD brain suggests astroglial activation and a 
concurrent immune response in the brain. 
Enhanced expression of the astrocytic marker GFAP in the 
striatum (upper panels) of 3-month BACHD shown by 
immunohistochemistry and western blot. In addition, an 
increase in the expression of the MHCII was observed in the 
BACHD mice, suggesting a concurrent immune response, due 
to activated microglia and possibly to immune cells from the 
periphery. 
 
 
 
 
 
 
Figure 6-1: Western blot and immunohistochemistry in 
BACHD striatum show axonal and myelin loss early in 
disease progression. 
Increased expression of SMI-32, a marker for axonal 
degeneration, and decreased levels of myelin marker MBP 
were observed in 3-month male BACHD brain (upper panels). 
Higher magnification insets show axon l bundles in the 
striatum. BACHD striatum also showed decreased axonal 
marker NF-160 immunoreactivity (lower panels). Western blot 
analyses showing lower levels of NF-160 (axon) and MBP 
(myelin) in the BACHD striatum. These results suggest that 
axonal and myelin loss begin early in disease progression. 
St=striatum, V=lateral ventricle, CC=corpus callosum 
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Table 13: Table 6-1: Primary antibodies were used at the following concentrations for 
immunohistochemistry (IHC) or western blot (WB): 
  
 
Markers Cell Type and Target IHC WB 
SMI32 Dephosphorylated Neurofilament (200kDa) 1:200  
NF160 Neurofilament (160kDa) 1:50 1:200 
MBP Myelin Basic Protein 1:1000 1:10000 
GFAP Astrocyte 1:500 1:5000 
MHCII Monocytes/macrophages 1:400  
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